

Professor Simon Cauchemez

Mathematical Modelling of Infectious Diseases Unit
Institut Pasteur
28 rue du Dr Roux, 75015 Paris, France
webpages: <https://research.pasteur.fr/fr/team/mathematical-modelling-of-infectious-diseases/>
<https://modelisation-covid19.pasteur.fr/>

Email: simon.cauchemez@pasteur.fr

POSITIONS

04/2023-now	Professor, Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Paris.
11/2013-03/2023	Research Director, Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Paris.
08/2013-10/2013	Reader in Statistical Infectious Disease Epidemiology, in the Department of Infectious Disease Epidemiology, Imperial College London, London.
08/2011-07/2013	Senior Lecturer in Statistical Infectious Disease Epidemiology, in the Department of Infectious Disease Epidemiology, Imperial College London, London.
04/2007-04/2012	RCUK Research Fellow in the Department of Infectious Disease Epidemiology, Imperial College London, London.
10/2005-03/2007	Post Doctoral Research Associate in the Department of Infectious Disease Epidemiology, Imperial College London, London.

EDUCATION

11/2017	Habilitation à Diriger des Recherches (HDR), Université Pierre et Marie Curie, Paris, France.
10/2002-12/2005	PhD in Biostatistics, Université Pierre et Marie Curie, Paris, France. Thesis title: Estimation of transmission parameters in epidemic models by Markov chain Monte Carlo sampling. Supervisors: Boëlle PY, Thomas G.
09/2001-07/2002	Master in Biomathematics, Université Pierre et Marie Curie, Paris, France. Bayesian analysis of influenza transmission: Application to a longitudinal follow-up of households. Supervisor: Boëlle PY. (1 st)
09/1998-09/2001	ENSAE in statistics / economics, Malakoff, France. ENSAE is the National School for Statistics and Economic Administration.

AWARDS & HONORS

2026-2027	Annual chair Technical Innovation Liliane Bettencourt, Collège de France.
2022	Chevalier de l'Ordre National de la Légion d'Honneur (Legion of Honor).
2022	Subvention scientifique Del Duca, Académie des sciences, budget : 120k €.
2021	Prix Lucien Tartoïs, Fondation pour la Recherche Médicale, budget : 20k €.
2020	Prix Lacassagne, Collège de France, budget : 6k €.
2019	Prix Louis-Daniel Beauperthuy, Académie des Sciences, 1.5k €.
2017	Prix Thérèse Lebrasseur, Fondation de France, budget: 50k €.
2017-2019	Chair of Excellence Elie Metchnikoff, Institut Pasteur.
2015	Grand Prix Robert Debré 2015, budget: 50k €.
2015-2019	AXA Award "Pandemic risk in Asia", award designed to support mid-career researchers with extremely high potential for innovation in their fields, budget: 250k €.
2009	Promising Investigator Award, Options for the control of Influenza VII, Hong Kong.
2006	Guy & Suzy Halimi Award, Chancellerie des Universités de Paris.

OTHER

Scientific advisory committees and working groups supporting health authorities

2025-2026	Member of Working Group assessing French antiviral stockpile for an influenza pandemic, French High Council for Public Health.
2024-2026	Leader of modelling activities supporting recommendations of French National Authority for Health on COVID-19, meningococcal and pneumococcal vaccines.
2022-2024	Member of COVARs, French committee for monitoring and anticipating health Risks.
2020-2022	Member of the COVID19 Scientific Council of the Ministry of Health, France.

Structuring of infectious disease modelling community in France

2021-now	Co-President of the Coordinated Action in charge of coordinating French research activities on the modelling of infectious diseases at the agency ANRS-MIE funding research on infectious diseases in France (ANRS-MIE AC Modelling).
----------	---

Editorial activities

2025-now	Academic Editor, <i>PLOS Medicine</i> Editorial Board.
2021-now	Member of the Board of Reviewing Editors of the journal <i>Science</i> .

Scientific advisory boards (SAB) for projects and research entities	
2026-now	Member of SAB of SYNERG-ID.
2025-now	Member of SAB and steering committee of InIndex Complexity, University Paris Cité, France.
2025-now	Member of SAB of the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Health Analytics and Modelling, UK.
2023-2025	Member of SAB of the MRC Center for Global Infectious Diseases Analysis, Imperial College London, UK.
2023-now	Member of SAB of Cegedim THIN.
2022-2025	Member of SAB of OptimAgent modelling project, Germany.
2022-2025	Member of SAB of the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Modelling and Health Economics, UK.
2022-now	Member of SAB of Domaine d'Intérêt Majeur (DIM) One Health, Région Ile de France.
2019-2021	Member of the steering committee of US NIGMS Models of Infectious Disease Agent Study (MIDAS).
2019-2025	Member of the steering committee of ArboFrance.
2017-now	Member of SAB of Institut Pasteur Madagascar.
2017-2020	Member of SAB of Institut Pasteur Cambodia.
2017-2020	Member of the steering committee of the INCEPTION program.
Teaching	
2026-2027	Annual chair Technical Innovation Liliane Bettencourt, Collège de France.
2021-now	Co-director of the 1-week course Modelling of Infectious Diseases, Institut Pasteur.
Evaluation panels	
2020-2024	Member of the Population and Public Health Expert Review Group, Wellcome Trust.
2018-2021	Member of COMESP, the committee in charge of evaluating scientists at Institut Pasteur. President of subcommittee about modelling, biostatistics and bioinformatics.

GRANTS

At Institut Pasteur

2026-2027	Gates Foundation, Strengthening mpox decision-making in the DRC through epidemic modelling and data analytics, Co-investigator, 54k \$.
2025-2028	PEPR PReViX “Pandemic preparedness to Respiratory Virus X: integrative modelling from first cases to early public health countermeasures”, Co-investigator, 194k €.
2026-2027	ANRS-MIE, Characterizing flavivirus antibody dynamics from a unique cohort in Nicaragua, Co-investigator, 60k €.
2025-2030	PEPR MathVives, Mathematical Modeling and Management of Emerging Arbovirose Epidemics, Co-investigator, 159k €.
2025-2026	Labex IBEID, “Analysis and modelling of infectious diseases epidemics to support evidence based policy making in France”, PI, 60k €.
2024-2031	Wellcome Trust, Risk Assessment Community Spread Multiple Endemic Infectious Pathogens (RACSMEI), co-Investigator, 460k €.
2024-2026	HAS, Modelling of vaccination strategies for HAS recommendations, PI, up to 200k €.
2024-2027	EU LEAPS, Integrating Multi-Disciplinary Expertise in a Learning and Adaptive European Pandemic Preparedness System, Co-investigator, 110k €.
2023-2027	EU DURABLE, Delivering a Unified Research Alliance of Biomedical and public health Laboratories against Epidemics, Workpackage leader, 515k €.
2023-2026	AXARF, Influenza virus antibody landscapes to decipher the drivers of influenza epidemics, PI, 291k €.
2023-2024	HAS, Modelling the impact of meningococcal vaccines, PI, 49k €.
2022-2024	ANRS-MIE, MPX-SPREAD, Characterizing the spreading dynamics of 2022 monkeypox outbreak in France to aid public health policies, Co-Investigator, 34k €.
2021-2023	ANRS-MIE, Project EMERGEN studying SARS-CoV-2 variants in France, co-PI for modelling, 150k €.
2021-2025	NIH, PICREID Inter-regional study of transmission, adaptation and pathogenesis of viruses with pandemic potential in Southeast Asia and West/Central Africa, Co-investigator, 220k \$.
2020-2022	HAS, Modelling SARS-CoV-2 vaccination strategies, PI, 30k €.
2020-2022	AXA, “Modelling SARS-CoV-2 transmission in France”, PI, 70k €.
2020-2023	Groupama, “Modelling SARS-CoV-2 transmission in France”, PI, 136k €.
2020-2025	EU H2020 VEO, Versatile Emerging infectious disease Observatory, Co-investigator, 198k €.
2020-2023	EU H2020 RECOVER, Rapid European SARS-CoV-2 Emergency Research Response, WP co-leader, 119k €.
2019-2023	Santé Publique France, “Modelling infectious disease epidemics in France”, PI, 150k €.
2018-2021	DARPA (US), Preempt project “Understanding arbovirus emergence and changing the approach to intervention”, co-investigator, 322k \$.
2017-2027	Labex IBEID “Analysis and modelling of infectious diseases epidemics to support evidence based policy making in France”, PI, 618k €.

2017-2020	EU consortium ZikAlliance, “A global alliance for Zika virus control and prevention”, leader of modelling task, 133k €.
2015-2019	NIH MIDAS INITIATIVE, “Models for synthesizing molecular, clinical and epidemiological data and translation to public health response”, Co-PI, 540k \$.
2015-2019	Labex IBEID “Better understanding the dynamics of spread of emerging infectious diseases in space and time”, PI, 232k €.
2015-2016	Institut Pasteur Defeat Dengue program, “Modelling the spatial-temporal dynamics of spread of dengue in Delhi, India”, PI, 24.5k €.

At Imperial College London

2011-2016	Predemics, funded by EU, co-investigator, £685k.
2009-2014	NIH MIDAS initiative, co-investigator (I wrote the initial draft of Imperial’s contribution), £768k.
2011-2013	“EMIT: Evaluating Models of Influenza Transmission using a Human Challenge Model”, funded by CDC, co-investigator (in charge of power calculation & statistical analysis; contributions to study design), £95k.
2008-2012	“Estimating the impact of social structure on epidemics and predicting the impact of targeted interventions”, funded by Medical Research Council, co-investigator (I wrote about half of the proposal), £579k.
2008-2012	“Vaccine Modelling Initiative”, funded by Bill and Melinda Gates Foundation, co-investigator (I wrote a section of the proposal), £1,508k.
2007-2012	RCUK Fellowship, £125k.
2009-2011	“Influenza virus shedding in relation to environmental contamination and infection control advice”, funded by NIHR, co-investigator (in charge of power calculation & statistical analysis), total budget £370,000, £3k.
2009-2010	Challenge study ITSDG, funded by Dept Health (England), co-investigator (in charge of power calculation & statistical analysis; contributions to study design), total budget £264k, £3k.

SUPERVISION

Postdocs and research engineers

11/25-now	A. Bizzotto.
10/2025-now	E. Gault.
09/2023-02/2026	K. Charniga (currently Public Health Officer at Singapore Communicable Diseases Agency).
07/2023-now	F. Camaglia.
06/2023-now	N. Ochida.
09/2022-now	L. Cristancho-Fajardo & M. Shin.
05/2022-now	A. Brault.
11/2020-02/2022	I. Achitouv (currently permanent research at Sorbonne Université).
01/2019-now	P. Bosetti.
06/2019-12/2020	T. Nemoto (currently Professor at the University of Osaka).
09/2017-08/2023	N. Hoze (currently Chargé de Recherche at INSERM).
01/2017-now	J. Paireau.
01/2017-03/2019	Q. TenBosch (currently Professor and Chair of Infectious Disease Epidemiology at Wageningen University).
01/2017-12/2018	A. Cousien (currently postdoc at INSERM).
01/2017-12/2017	M. Saccareau (co-sup with B. Durand).
09/2015-12/2019	B. Nikolay (currently epidemiologist at Epicentre).
02/2015-04/2022	A. Andronico (currently machine learning engineer at Liftoff Mobile).
02/2015-04/2018	M. Churakov (currently data scientist at BNP Paribas Cardif).
02/2014-07/2015	I. Votsi (currently Assistant Professor at Université de Lorraine).
12/2013-07/2014	E. Babykina (Maître de conférences at Université de Lille).
04/2012-10/2013	P. Nouvellet (co-sup with C. Donnelly; currently Professor at University of Sussex).
01/2011-07/2013	I. Dorigatti (co-sup with N. Ferguson; currently Associate Professor at Imperial College).
02/2011-08/2013	M. Gambhir (co-sup with N. Ferguson; currently Principal Scientist at MSD).
01/2011-08/2012	L. Opatowski (co-sup with N. Ferguson; currently Professor at UVSQ).
11/2010-04/2012	A. Cori (currently Associate Professor at Imperial College), C. Pelat (currently biostatistician at Santé Publique France) (both co-sup with C. Fraser & N. Ferguson).

PhD students

9/25-now	L. Duret (co-sup with M. White).
1/2025-now	I. Yalikun (co-sup with P. Bosetti).
10/2023-now	M. Shin (co-sup with J. Paireau).
09/2022-now	C. Perlant (co-sup with P. Bosetti; currently postdoc at Université de Genève).
10/2021-now	T. Cortier.
10/2019-12/2022	M. Layan (co-sup with H. Bourhy; currently postdoc at ENS).
10/2019-09/2022	C. Tran Kiem (currently Wellcome Trust Fellow at Imperial College).
10/2017-12/2021	C. Eisenhauer (co-sup. with H. Salje; currently epidemiologist at Epicentre).
09/2016-12/2019	N. Courtejoie (co-sup with B. Durand; currently data scientist at DREES).
05/2014-12/2015	T. Tsang (co-sup with B. Cowling; currently Assistant Professor at Hong Kong University).

10/2012-05/2016	N. Imai (co-sup with N. Ferguson; currently at the Wellcome Trust).
11/2007-06/2011	R. Eggo (co-sup with N. Ferguson; currently Professor at London School of Hygien and Tropical Medicine).
11/2007-05/2011	P. Walker (co-sup with A. Ghani; passed; currently: Associate Professor at Imperial College London).
10/2006-01/2010	I. Cremin (co-sup with G. Garnett; passed).

Master students

01/2025-06/2025	L. Duret.
06/2023-11/2023	J. Dowding.
09/2022-02/2023	L. Tamaraikkannan.
04/2019-09/2019	M. Lavan.
02/2019-07/2019	F. Mazzamurro.
01/2018-07/2018	M. Najm.
09/2016-02/2017	M. Sandfort.
07/2016-09/2016	C. Eisenhauer.
02/2016-08/2016	A. Robert.
07/2015	M. Jendrosseck.
06/2015-08/2015	M. Calvo Cortes.
07/2015-08/2015	C. Fortas.

PUBLICATIONS

- O'Driscoll M, Hozé N, Lefrancq N, dos Santos GR, Hoinard D, Rahman MZ, Paul KK, Titu AN, Alam MS, Hossain ME, Mohammad E, Vanhomwegen J, [Cauchemez S](#), Gurley ES, Salje H. Epidemiological and antigenic inferences from serological cross-reactivity among arboviruses. *Science Translational Medicine* 2025; 17(826): eads8680.
- Cauchemez S. Now is the time to integrate serology into routine infectious disease surveillance. *Lancet Infectious Diseases* 2026; 26:2-3.
- Hoy G, Cortier T, Maier HE, Kuan G, Lopez R, Sanchez N, Ojeda S, Plazaola M, Stadlbauer D, Shotwell A, Balmaseda A, Krammer F, [Cauchemez S](#)*, Gordon A*. Anti-neuraminidase and anti-HA stalk antibodies reduce the susceptibility to and infectivity of influenza A/H3N2 virus. *Nature Communications* 2025; 16, 10910. * Equal contribution.
- Cristancho-Fajardo L, Nkuba-Ndaye A, Simons E, Hozé N, Guichet E, Asuni Izia Y, Ateba Ndongo F, Mbala-Kingebeni P, Aissata Soumah A, Muzinga J, Tshiminyi-Munkamba P, Saliou Kalifa Diallo M, Zoung-Kanyi Bissek AC, Makiala-Mandanda S, Toure A, Ahuka-Mundekes S, Ayoub A, Etard JF, Peeters M, Roche B, Nikolay B, Delaporte E, [Cauchemez S](#). Assessing SARS-CoV-2 transmission in African households from the reanalysis of serosurveys. *American Journal of Epidemiology* 2025; kwaf269.
- Perlant C, Weill F-X, Paireau J, Scipioni M, Bosetti P, [Cauchemez S](#). Modeling the spatio-temporal spread of cholera in France in 1892. *Epidemics* 2025; 53:100872.
- Bosetti P, Peckeu-Abboud L, Andrianasolo RM, Baguelin M, Fonteneau L, Deghamne AE, Taha MK, Barret AS, Grimprel E, Opatowski L, Lévy-Bruhl D, [Cauchemez S](#). Modelling the impact of a quadrivalent ACWY meningococcal vaccination and vaccination targeting serogroup B in France. *Vaccine* 2025; 67:127871.
- Rasoamalala F, Ramasindrazana B, Parany MJ, Rahajandraibe S, Randrianseho L, Rahelinirina S, Gorgé O, Valade E, Harimalala M, Rajerison M, [Cauchemez S](#)*, Brault A*. Unraveling the role of rat and flea population dynamics on the seasonality of plague epidemics in Madagascar. *PNAS* 2025; 122 (24); e2502161122. * Equal contribution.
- dos Santos GR, Jawed F, Mukandavire C, Deol A, Scarponi D, Mboera LEG, Seruyange E, Poirier MJP, Bosomprah S, Udeze AO, Dellagi K, Hozé N, Chilongola J, Nasrallah GK, [Cauchemez S](#), Salje H. Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns. *Nature Medicine* 2025; 10.1038/s41591-025-03703-w.
- Pérez-Estigarribia PE, dos Santos GR, [Cauchemez S](#), Vazquez C, Ibarrola-Vannucci AK, Sequera G, Villalba S, Ortega MJ, Di Fabio JL, Scarponi D, Mukandavire C, Deol A, Cabello A, Vargas E, Fernández C, León L, Salje, H. Modeling the impact of vaccine campaigns on the epidemic transmission dynamics of chikungunya virus outbreaks. *Nature Medicine* 2025; 10.1038/s41591-025-03684-w.
- Kraemer MUG, Tsui JLH, Chang SY, Lytras S, Khurana MP, Vanderslott S, Bajaj S, Scheidwasser N, Curran-Sebastian JL, Semenova E, Zhang MY, Unwin HJT, Watson OJ, Mills C, Dasgupta A, Ferretti L, Scarpino SV, Koua E, Morgan O, Tegally H, Paquet U, Moutsianas L, Fraser C, Ferguson NM, Topol EJ, Duchêne DA, Stadler T, Kingori P, Parker MJ, Dominici F, Shadbolt N, Suchard MA, Ratmann O, Flaxman S, Holmes EC, Gomez-Rodriguez M, Schölkopf B, Donnelly CA, Pybus OG, [Cauchemez S](#)*, Bhatt S*. Artificial intelligence for modelling infectious disease epidemics. *Nature* 2025; 638 (8051): 623-635. * Equal contribution.
- Perlant C, Klitting R, Colizza V, Gaythorpe KAM, Gabiane G, de Lamballerie X, Failloux AB, [Cauchemez S](#)*, Bosetti P*. A framework to assess the risk of yellow fever emergence. *Journal of Travel Medicine* 2025; 32: 10.1093/jtm/taaf081. * Equal contribution.
- Menezes A, Hay JA, Razafindratsimandresy R, Randriamanantena AH, Yang LJ, Héraud JM, [Cauchemez S](#), Wesolowski A, Grenfell B, Graham AL, Metcalf. Revealing trends in measles immunity during periods of varying measles circulation in Madagascar. *American Journal of Epidemiology* 2025; DOI10.1093/aje/kwaf005.
- Chauvel C, Casalegno J, Visseaux B, Vieillefond V, Haim-Boukozba S, Enouf V, Chanard E, Fabre M, Rameix-Welti M, Oblette A, Giannoli J, Paireau J, Josset L, Lina B, Gaymard A, [Cauchemez S](#), Morfin F, Nunes MC, Bal A. Community and Hospital-Based Laboratory Surveillance for Influenza, Respiratory Syncytial Virus, and SARS-CoV-2 During the 2023-2024 Season, Lyon, France. *Journal of Medical Virology* 2025; 97:e70549.
- Brady OJ, Bastos LS, Caldwell JM, [Cauchemez S](#), Clapham HE, Dorigatti I, Gaythorpe KAM, Hu WB, Hussain-Alkhateeb L, Johansson MA, Lim A, Lopez VK, Maude RJ, Messina JP, Mordecai EA, Peterson AT, Rodriguez-Barraquer I, Rabe IB, Rojas DP, Ryan SJ, Salje H, Semenza JC, Tran, QM. Why the growth of arboviral diseases necessitates a new generation of global risk maps and future projections. *PLoS Comp Biol* 2025; 21(4): e1012771.
- Macaux L, Rasolofo V, Eyangoh S, N'Guessan KR, Tejiokem MC, Rakotosamimanana N, Soumahoro MK, [Cauchemez S](#)*, Rendremanana RV*. Accuracy of Xpert and alternative sampling methods to diagnose childhood pulmonary tuberculosis, a prospective cohort study. *Clinical Microbiology and Infection* 2025; 31(3):417-424. * Equal contribution.
- Cortier T, Gilboa M, Layan M, Joseph G, Meltzer L, Amit S, Rubin C, Lustig Y, Alroy-Preis S, Kreiss Y, [Cauchemez S](#)*, Regev-Yochay G*. Factors Associated With the Transmission of the Delta Severe Acute Respiratory Syndrome Coronavirus 2 Variant in

Households: The Israeli COVID-19 Family Study (ICoFS). Journal of Infectious Diseases 2025; 231(4):e734-e742. * Equal contribution.

17. Soussand F, Abdou AY, Sanchez M, Huynh BT, Giese C, Tran-Kiem C, Béraud G, Guillemot D, Cauchemez S, Opatowski L, Bosetti P. Evolution of social contacts patterns in France over the SARS-CoV-2 pandemic: results from the SocialCov survey. BMC Infectious Diseases 2025; 25(1):224.
18. Cuartero CT, Carnegie AC, Cucunuba ZM, Cori A, Hollis SM, Gaalen RDV, Baidjoe AcY, Spina AF, Lees JA, Cauchemez S, Santos M, Umana J, Chen CR, Gruson H, Gupte P, Tsui JS, Shah AA, Millan GG, Quevedo DS, Batra N, Torneri A, Kucharski AJ. From the 100 Day Mission to 100 lines of software development: how to improve early outbreak analytics. Lancet Digital Health 2025; 7(2):e161-e166.
19. **Hoze N, Pons-Salort M, Metcalf CJE, White M, Salje H, Cauchemez S, RSero: A user-friendly R package to reconstruct pathogen circulation history from seroprevalence studies. PLoS Comp Biol 2025; 21(2): e1012777.**
20. Traore A, Charniga K, Grellet S, Terpent G, Da Cruz H, Lamy A, Thomas N, Gbaguidi G, Mercier A, Prudhomme J, Visseaux B, Giannoli JM, Vieillefond V, Haim-Boukoba S, Castro-Alvarez J, Kouamen AC, Rameix-Welti MA, Beirerra-Ibraim S, Destras G, Josset L, Cauchemez S, Lina B, Coignard B, Schaeffer J, Enouf V, Bal A. Monitoring SARS-CoV-2 variants with complementary surveillance systems: risk evaluation of the Omicron JN.1 variant in France, August 2023 to January 2024. Eurosurveillance 2025; 30(1):2400293.
21. Andronico A, Paireau J, Cauchemez S. Integrating information from historical data into mechanistic models for influenza forecasting. PLoS Computational Biology 2024; 20:e1012523.
22. Charniga K, Park SW, Akhmetzhanov AR, Cori A, Dushoff, J, Funk S, Gostic KM, Linton NM, Lison A, Overton CE, Pulliam JRC, Ward T, Cauchemez S, Abbott S. Best practices for estimating and reporting epidemiological delay distributions of infectious diseases. PLoS Computational Biology 2024; 20:e1012520.
23. Layan M, Hens N, de Hoog MLA, Bruijning-Verhagen PCJL, Cowling BJ, Cauchemez S. Addressing current limitations of household transmission studies by collecting contact data. AJE 2024; kwae106.
24. **Brault A, Pontais I, Enouf V, Debeuret C, Bloch E, Paireau J, Rameix-Welti MA, White M, Baudemont G, Lina B, Parent du Châtelet I, Casalegno JS, Vaux S, Cauchemez S. Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study. Lancet Child and Adolescent Health 2024; 8:721-729.**
25. Duque MP, Naser A, dos Santos GR, O'Driscoll M, Paul KK, Rahman M, Alam MS, Al-Amin HM, Rahman MZ, Hossain ME, Paul RC, Luby SP, Cauchemez S, Vanhomwegen J, Gurley ES, Salje H. Informing an investment case for Japanese encephalitis vaccine introduction in Bangladesh. Science Advances 2024; 10:eadp1657.
26. Chen Y, Xu Y, Wang L, Liang Y, Li N, Lourenço J, Yang Y, Lin Q, Wang L, Zhao H, Cazelles B, Song H, Liu Z, Wang Z, Brady OJ, Cauchemez S*, Tian H*. Indian Ocean temperature anomalies predict long-term global dengue trends. Science 2024; 384:639-646. * Equal contribution.
27. Wang L, Huang AT, Katzelnick LC, Lefrancq N, Escoto AC, Duret L, Chowdhury N, Jarman R, Conte MA, Berry IM, Fernandez S, Klungthong C, Thaisomboonsuk B, Suntaratiwong P, Vandepitte W, Whitehead SS, Cauchemez S, Cummings DAT, Salje H. Antigenic distance between primary and secondary dengue infections correlates with disease risk. Science Translational Medicine 2024; 16: eadk3259.
28. Nunes MC, Thommes E, Fröhlich H, Flahault A, Arino J, Baguelin M, Biggerstaff M, Bizel-Bizellot G, Borchering R, Cacciapaglia G, Cauchemez S, Barbier-Chebbah A, Claussen C, Choirat C, Cojocar M, Commaillie-Chapus C, Hon C, Kong J, Lambert N, Lauer KB, Lehr T, Mahe C, Marechal V, Mebarki A, Moghadas S, Niehus R, Opatowski L, Parino F, Pruvost G, Schuppert A, Thiébaut R, Thomas-Bachli A, Viboud C, Wu J, Crépey P, Coudeville L. Redefining pandemic preparedness: Multidisciplinary insights from the CERP modelling workshop in infectious diseases, workshop report. Infect Dis Model 2024; 9:501-518.
29. **Andronico A, Menudier L, Salje H, Vincent M, Paireau J, de Valk, H, Gallian P, Pastorino B, Brady O, de Lamballerie X, Lazarus C, Paty MC, Vilain P, Noel H, Cauchemez S. Comparing the performance of three models incorporating weather data to forecast dengue epidemics in Reunion island, 2018-2019. Journal of Infectious Diseases 2024; 10.1093/infdis/jiad468.**
30. Tan-Lhernould L, Tamandjou C, Deschamps G, Platon J, Sommen C, Chereau F, du Chatelet IP, Cauchemez S, Vaux S, Paireau J. Impact of vaccination against severe COVID-19 in the French population aged 50 years and above: a retrospective population-based study. BMC Medicine 2024; 21:426.
31. Franconeri L, Antona D, Cauchemez S, Lévy-Bruhl D, Paireau J. Two-doses measles vaccine effectiveness remains high over time: a French observational study, 2017-2019. Vaccine 2023; 41:5797-5804.
32. Tsui J, McCrone JT, Lambert B, Bajaj S, Inward RPD, Bosetti P, Pena RE, Tegally H, Hill V, Zarebski AE, Peacock TP, Liu L, Wu N, Davis M, Bogoch II, Khan K, Kall M, Aziz NIBA, Colquhoun R, O'Toole A, Jackson B, Dasgupta A, Wilkinson E, de Oliveira T, Connor TR, Loman NJ, Colizza V, Fraser C, Volz E, Ji X, Gutierrez B, Chand M, Dellicour S, Cauchemez S*, Raghwani J*, Suchard MA*, Lemey P*, Rambaut A*, Pybus OG*, Kraemer MUG*. Genomic assessment of invasion dynamics of SARS-CoV-2 Omicron BA.1. Science 2023; 381:336-343. * Equal contribution.
33. Bhatia S, Imai N, Watson OJ, Abbood A, Abdelmalik P, Cornelissen T, Ghazzi S, Lassmann B, Nagesh R, Ragonnet-Cronin ML, Schnitzler JC, Kraemer MU, Cauchemez S, Nouvellet P, Cori A. Lessons from COVID-19 for rescalable data collection. Lancet Infectious Diseases 2023; 23:E227-E227.
34. Lefrançois T, Lina B, COVARIS, Autran B. One Health approach at the heart of the French Committee for monitoring and anticipating health risks. Nat Com 2023; 14:7540.
35. Woudenberg T, Pinaud L, Garcia L, Tondeur L, Pelleau S, De Thoisy A, Donnadieu F, Backovic M, Attia M, Hoze N, Duru C, Koffi AD, Castelain S, Ungeheuer MN, Pellerin SF, Planas D, Bruel T, Cauchemez S, Schwartz O, Fontanet A, White M. Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021. Eurosurveillance 2023; 28:2200681.
36. Bauzile B, Durand B, Lambert S, Rautureau S, Fourtune L, Guinat C, Andronico A, Cauchemez S, Paul MC, Vergne T. Impact of palmiped farm density on the resilience of the poultry sector to highly pathogenic avian influenza H5N8 in France. Veterinary research 2023; 54:56.
37. Galmiche S, Cortier T, Charmet T, Schaeffer L, Chény O, von Platen C, Lévy A, Martin S, Omar F, David C, Mailles A, Carrat F, Cauchemez S, Fontanet A. SARS-CoV-2 incubation period across variants of concern, individual factors, and circumstances of infection in France: a case series analysis from the ComCor study. Lancet Microbe 2023; S2666-5247(23)00005-8.
38. Paireau J, Charpignon ML, Larrieu S, Calba C, Hoze N, Boelle PY, Thiebaut R, Prague M, Cauchemez S. Impact of non-pharmaceutical interventions, weather, vaccination, and variants on COVID-19 transmission across departments in France. BMC Infectious Diseases 2023; 23:190.
39. Laydon DJ, Cauchemez S, Hinsley WR, Bhatt S, Ferguson NM. Impact of proactive and reactive vaccination strategies for health-care workers against MERS-CoV: a mathematical modelling study. Lancet Glob Health 2023 ;11(5):e759-e769.
40. Tsang TK, Huang X, Wang C, Chen S, Yang B, Cauchemez S*, Cowling BJ*. The effect of variation of individual infectiousness on SARS-CoV-2 transmission in households. Elife 2023; 12:e82611. * Equal contribution.

41. Layan M, Müller NF, Dellicour S, De Maio N, Bourhy H, Cauchemez S^{*}, Baele G^{*}. Impact and mitigation of sampling bias to determine viral spread: Evaluating discrete phylogeography through CTMC modeling and structured coalescent model approximations. *Virus Evol* 2023; 9:vead010. ^{*} Equal contribution.
42. **Cauchemez S, Bosetti P, Cowling BJ. Managing sources of error during pandemics. *Science* 2023; 379:437-439.**
43. Gallian P, Hozé N, Brisbarre N, Saba Villarroel PM, Nurtop E, Isnard C, Pastorino B, Richard P, Morel P, Cauchemez S, de Lamballerie X. SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021. *iScience* 2023; 26:106222.
44. Roux J, Massonnaud CR, Colizza V, Cauchemez S, Crépey P. Modeling the impact of national and regional lockdowns on the 2020 spring wave of COVID-19 in France. *Sci Rep* 2023; 13:1834.
45. Ochida N, Dupont-Rouzeyrol M, Moury PH, Demaneuf T, Gourinat AC, Mabon S, Jouan M, Cauchemez S, Mangeas M. Evaluating the strategies to control SARS-CoV-2 Delta variant spread in New Caledonia, a zero-COVID country until September 2021. *IJID Reg* 2023; 8:64-70.
46. Yang J, Liao Q, Luo K, Liu F, Zhou Y, Zou G, Huang W, Yu S, Wei X, Zhou J, Dai B, Qiu Q, Altmeyer R, Hu H, Paireau J, Luo L, Gao L, Nikolay B, Hu S, Xing W, Wu P, van Doorn HR, Horby PW, Simmonds P, Leung GM, Cowling BJ, Cauchemez S, Yu H. Seroepidemiology of enterovirus A71 infection in prospective cohort studies of children in southern China, 2013-2018. *Nat Com* 2022; 13(1):7280.
47. Brault A, Tran-Kiem C, Couteaux C, Olié V, Paireau J, Yazdanpanah Y, Ghosn J, Martin-Blondel G, Bosetti P, Cauchemez S. Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna. *Lancet Reg Health West Pac* 2022; 30: 100634.
48. Zhou J, Zhou Y, Luo K, Liao Q, Zheng W, Gong H, Shi H, Zhao S, Wang K, Qiu Q, Dai B, Ren L, Wang L, Gao L, Xu M, Liu N, Lu W, Zheng N, Chen X, Chen Z, Yang J, Cauchemez S, Yu H. The transfer of maternal antibodies and dynamics of maternal and natural infection-induced antibodies against coxsackievirus A16 in Chinese children 0-13 years of age: a longitudinal cohort study. *BMC Med* 2022; 20:436.
49. Tsang TK, Wang C, Fang VJ, Perera RAPM, So HC, Ip DKM, Peiris JSM, Leung GM, Cauchemez S^{*}, Cowling BJ^{*}. Indirect Protection from Vaccinating Children against Influenza A Virus Infection in Households. *Viruses* 2022; 14:2097. ^{*} Equal contribution.
50. Nemoto T, Aubry M, Teissier Y, Paul R, Cao-Lormeau VM, Salje H, Cauchemez S. Reconstructing long-term dengue virus immunity in French Polynesia. *PLoS NTD* 2022; 16: e0010367.
51. **Ten Bosch Q, Andrianaiivoarimanana V, Ramasindrazana B, Mikaty G, Rakotonanahary RJL, Nikolay B, Rahajandraibe S, Feher M, Grassin Q, Paireau J, Rahelinirina S, Randremananana R, Rakotoarimanana F, Melocco M, Rasolofo V, Pizarro-Cerdá J, Le Guern AS, Bertherat E, Ratsitorahina M, Spiegel A, Baril L, Rajerison M, Cauchemez S. Analytical framework to evaluate and optimize the use of imperfect diagnostics to inform outbreak response: Application to the 2017 plague epidemic in Madagascar. *PLoS Biology* 2022; 20:e3001736.**
52. **Blanquart F, Hozé N, Cowling BJ, Debarre F, Cauchemez S. Selection for infectivity profiles in slow and fast epidemics, and the rise of SARS-CoV-2 variants. *Elife* 2022; 11 : e75791.**
53. **Paireau J, Andronico A, Hozé N, Layan M, Crépey P, Roumagnac A, Lavielle M, Boelle PY, Cauchemez S. An ensemble model based on early predictors to forecast COVID-19 healthcare demand in France. *PNAS* 2022; 119: e2103302119.**
54. Bailly S, Hozé N, Bissler S, Zhu-Soubise A, Fritzell C, Fernandes-Pellerin S, Mbouangoro A, Rousset D, Djossou F, Cauchemez S^{*}, Flamand C^{*}. Transmission dynamics of Q fever in French Guiana: A population-based cross-sectional study. *Lancet Regional Health Americas* 2022; 16:100385. ^{*} Equal contribution.
55. Christofferson RC, Wearing HJ, Turner EA, Walsh CS, Salje H, Tran Kiem C, Cauchemez S. How do I bite thee? Let me count the ways: exploring the implications of individual biting habits of *Aedes aegypti* for dengue transmission. *PLoS NTD* 2022; 16:e0010818.
56. Lefrancq N, Bouchez V, Fernandes N, Barkoff AM, Bosch T, Dalby T, Akerlund T, Darenberg J, Fabianova K, Vestreheim DF, Fry NK, Gonzalez-Lopez JJ, Gullisby K, Habington A, He QS, Litt D, Martini H, Pierard D, Stefanelli P, Stegger M, Zavadilova J, Armatys N, Landier A, Guillot S, Hong SL, Lemey P, Parkhill J, Toubiana J, Cauchemez S, Salje H, Brisse S. Global spatial dynamics and vaccine-induced fitness changes of *Bordetella pertussis*. *Science Translational Medicine* 2022; 14:eabn3253.
57. Colosi E, Bassignana G, Contreras DA, Poirier C, Boëlle PY, Cauchemez S, Yazdanpanah Y, Lina B, Fontanet A, Barrat A, Colizza V. Screening and vaccination against COVID-19 to minimize school closure: a modelling study. *Lancet Infectious Diseases* 2022; 10.1016/S1473-3099(22)00138-4.
58. Metcalf CJE, Paireau J, O'Driscoll M, Pivette M, Hubert B, Pontais I, Nickbakhsh S, Cummings DAT, Cauchemez S, Salje H. Comparing the age and sex trajectories of SARS-CoV-2 morbidity and mortality with other respiratory pathogens. *R Soc Open Sci* 2022; 9:211498.
59. Faucher B, Assab R, Roux J, Levy-Bruhl D, C Tran Kiem, Cauchemez S, Zanetti L, Colizza V, Boelle PY, Polettot C. Agent-based modelling of reactive vaccination of workplaces and schools against COVID-19. *Nature Communications* 2022; 13:1414.
60. **Tsang TK, Perera RAPM, Fang VJ, Wong JY, Shiu EY, So HC, Ip DKM, Malik Peiris JS, Leung GM, Cowling BJ, Cauchemez S. Reconstructing antibody dynamics to estimate the risk of influenza virus infection. *Nature Communications* 2022; 13(1):1557.**
61. **Layan M, Gilboa M, Gonen T, Goldenfeld M, Meltzer L, Andronico A, Hozé N, Cauchemez S^{*}, Regev-Yochay G^{*}. Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study. *American Journal of Epidemiology* 2022; kwac042. ^{*} Equal contribution.**
62. Razafimahatratra SL, Menezes A, Wesolowski A, Rafetrarivony L, Cauchemez S, Razafindratsimandresy R, Harimanana A, Crucitti T, Collard JM, Metcalf CJE. Leveraging serology to titrate immunisation programme functionality for diphtheria in Madagascar. *Epidemiol Infect* 2022; 150:e39.
63. Paireau J, Mailles A, Eisenhauer C, de Laval F, Delon F, Bosetti P, Salje H, Pontis V, Cauchemez S. Early chains of transmission of COVID-19 in France, January to March 2020. *Eurosurveillance* 2022; 2001953.
64. **Paireau J, Guillo S, El Belghiti FA, Matczak S, Tromber-Paolantini S, Giacomo V, Tha MK, Salje H, Brisse S, Levy-Bruhl D, Cauchemez S^{*}, Toubiana J^{*}. Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study. *Lancet Infectious Diseases* 2022; 22:265-273. ^{*} Equal contribution.**
65. Bosetti P, Tran Kiem C, Andronico A, Colizza V, Yazdanpanah Y, Fontanet A, Benamouzig D, Cauchemez S. Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modelling study applied to France. *BMC Med* 2022; 20:33.
66. Bosetti P, Tran Kiem C, Andronico A, Paireau J, Levy-Bruhl D, Alter L, Fontanet A, Cauchemez S. Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/2022. *Eurosurveillance* 2022; 2101125.
67. Sofonea MT, Cauchemez S, Boëlle PY. Epidemic models why and how to use them. *Anaesth Crit Care Pain Med*. 2022 ; 41(2):101048.
68. Grant R, Charmet T, Schaeffer L, Galmiche S, Madec Y, Von Platen C, Chény O, Omar F, David C, Rogoff A, Paireau J, Cauchemez S, Carrat F, Septfonds A, Levy-Bruhl D, Mailles A, Fontanet A. Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France. *Lancet Regional Health Europe* 2022; 13:100278.

69. Shirreff G, Zahar JR, [Cauchemez S](#), Temime L, Opatowski L; EMEA-MESuRS Working Group on the Nosocomial Modelling of SARS-CoV-2. Measuring basic reproduction number to assess effects of nonpharmaceutical interventions on nosocomial SARS-CoV-2 transmission. *EID* 2022; 28:1345-1354.
70. Di Domenico L, Sabbatini CE, Boëlle PY, Poletto C, Crépey P, Paireau J, [Cauchemez S](#), Beck F, Noel H, Lévy-Bruhl D, Colizza V. Adherence and sustainability of interventions informing optimal control against the COVID-19 pandemic. *Commun Med* 2021; 10.1038/s43856-021-00057-5.
71. Hoze N, Diarra I, Sangare AK, Pastorino B, Pezzi L, Kouriba B, Sagara I, Dabo A, Djimde A, Thera MA, Doumbo OK, de Lamballerie X, [Cauchemez S](#). Model-based assessment of Chikungunya and O'nyong-nyong virus circulation in Mali in a serological cross-reactivity context. *Nature Communications* 2021; 12: 6735.
72. Tran Kiem C, Bosetti P, Paireau J, Crépey P, Salje H, Lefrancq N, Fontanet A, Benamouzig D, Boelle PY, Desenclos JC, Opatowski L, [Cauchemez S](#). SARS-CoV-2 transmission across age groups in France and implications for control. *Nature Communications* 2021; 12: 6895.
73. Nikolay B, Ribeiro Dos Santos G, Lipsitch M, Rahman M, Luby SP, Salje H, Gurley ES, [Cauchemez S](#). Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh. *Vaccine* 2021; S0264-410X(21)01047-1.
74. Salje H, Wesolowski A, Brown TS, Kiang MV, Berry IM, Lefrancq N, Fernandez S, Jarman RG, Ruchusatsawat K, Iamsirithaworn S, Vandepitte WP, Suntaratiwong P, Read JM, Klungthong C, Thaisomboonsuk B, Engo-Monsen K, Buckee C*, [Cauchemez S*](#), Cummings DAT*. Reconstructing unseen transmission events to infer dengue dynamics from viral sequences. *Nature Communications* 2021; 12:1810. * Equal contribution.
75. Hoze N, Paireau J, Lapidus N, Tran Kiem C, Salje H, Severi G, Touvier M, Zins M, de Lamballerie X, Lévy-Bruhl D, Carrat F, [Cauchemez S](#). Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalization and serological data: a modelling study. *Lancet Public Health* 2021; S2468-2667.
76. Tran Kiem C, Andronico A, Bosetti P, Paireau J, Alter L, Boëlle PY, Fontanet A, Lévy-Bruhl D, [Cauchemez S](#). Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021. *Euro Surveill* 2021; 26:2100533.
77. Lefrancq N, Paireau J, Hozé N, Courtejoie N, Yazdanpanah Y, Bouadma L, Boëlle PY, Chereau F, Salje H, [Cauchemez S](#). Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance data analysis. *Lancet Reg Health Eur* 2021; 5:100087.
78. Bosetti P, Huynh BT, Abdou AY, Sanchez M, Eisenhauer C, Courtejoie N, Accardo J, Salje H, Guillemot D, Moslonka-Lefebvre M, Boelle PY, Beraud G, [Cauchemez S*](#), Opatowski L*. Lockdown impact on age-specific contact patterns and behaviours, France, April 2020. *Eurosurveillance* 2021; 26: PII 2001636. * Equal contribution.
79. Tsang TK, Wang C, Yang BY, [Cauchemez S*](#), Cowling BJ*. Using secondary cases to characterize the severity of an emerging or re-emerging infection. *Nature Communications* 2021; 12:6372. * Equal contribution.
80. Bosetti P, Tran Kiem C, Yazdanpanah Y, Fontanet A, Lina B, Colizza V, [Cauchemez S](#). Impact of mass testing during an epidemic rebound of SARS-CoV-2: a modelling study using the example of France. *Eurosurveillance* 2021; 26:8-14.
81. Bailly S, Rousset D, Fritzell C, Hozé N, Ben Achour S, Berthelot L, Enfissi A, Vanhomwegen J, Salje H, Fernandes-Pellerin S, Saout M, Lavergne A, Manuguerra JC, Carod JF, Djossou F, [Cauchemez S](#), Flamand C. Spatial distribution and burden of emerging arboviruses in French Guiana. *Viruses*, 2021; 13:1299.
82. Flamand C, Sarmiento CA, Enfissi A, Bailly S, Beillard E, Gaillet M, Michaud C, Servas V, Clement N, Perilhou A, Carage T, Musso D, Carod JF, Eustache S, Tourbillon C, Boizon E, James S, Djossou F, Salje H, [Cauchemez S*](#), Rousset D*. Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020. *PLoS NTD* 2021; 15:e0009945. * Equal contribution.
83. Kraemer MUG, Hill V, Ruis C, Dellicour S, Bajaj S, McCrone JT, Baele G, Parag KV, Battle AL, Gutierrez B, Jackson B, Colquhoun R, O'Toole A, Klein B, Vespijnani A, COVID-19 Genomics UK (COG-UK) Consortium, Volz E, Faria NR, Aanensen DM, Loman NJ, du Plessis L, [Cauchemez S](#), Rambaut A, Scarpino SV, Pybus OG. Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. *Science* 2021; 373:889-895.
84. Moura A, Lefrancq N, Wirth T, Leclercq A, Borges V, Gilpin B, Dallman TJ, Frey J, Franz E, Nielsen EM, Thomas J, Pightling A, Howden BP, Tarr C, Gerner-Smidt P, [Cauchemez S](#), Salje H, Brisse S, Lecuit M. Emergence and global spread of *Listeria monocytogenes* main clinical clonal complex. *Science Advances* 2021; 7: eabj9805.
85. Kraemer MUG, Pybus OG, Fraser C, [Cauchemez S](#), Rambaut A, Cowling BJ. Monitoring key epidemiological parameters of SARS-CoV-2 transmission. *Nature Medicine* 2021; 27: 1854-1855.
86. [Cauchemez S](#), Bosetti P. A reconstruction of early cryptic COVID spread. *Nature* 2021; 21:40-41.
87. [Cauchemez S](#), Tran Kiem C. Managing COVID-19 importation risks in a heterogeneous world. *Lancet Public Health* 2021; S2468-S667(21000188-2).
88. Charmet T, Schaeffer L, Grant R, Galmiche S, Chény O, Von Platen C, Maurizot A, Rogoff A, Omar F, David C, Septfonds A, [Cauchemez S](#), Gaymard A, Lina B, Lefrançois LH, Enouf V, van der Werf S, Mailles A, Levy-Bruhl D, Carrat F, Fontanet A. Impact of original B.1.1.7 and B.1.351/P.1 SARS-COV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. *Lancet Reg Health Eur* 2021; 8:100171
89. Andronico A, Tran Kiem C, Paireau J, Succo T, Bosetti P, Lefrancq N, Nacher M, Djossou F, Sanna A, Flamand C, Salje H, Rousseau C, [Cauchemez S](#). Evaluating the impact of curfews and other measures on SARS-CoV-2 transmission in French Guiana. *Nature Communications* 2021; 1634.
90. Tran Kiem C, Massonnaud CR, Levy-Bruhl D, Poletto C, Colizza V, Bosetti P, Fontanet A, Gabet A, Olié V, Zanetti L, Boëlle PY, Crépey P, [Cauchemez S](#). A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures. *EClinicalMedicine* 2021; 38:101001.
91. [Cauchemez S](#), Bosetti P, Kiem CT, Mouro V, Consoli A, Fontanet A. Education and mental health: good reasons to vaccinate children. *Lancet* 2021; 398:387.
92. Ukita M, Hozé N, Nemoto T, [Cauchemez S](#), Asakura S, Makingi G, Kazwala R, Makita K. Quantitative evaluation of the infection dynamics of bovine brucellosis in Tanzania. *Prev Vet Med* 2021; 194:105425.
93. Andrianaivoarimanana V, Wagner DM, Birdsell DN, Nikolay B, Rakotoarimanana F, Randriantseheno LN, Vogler AJ, Sahl JW, Hall CM, Somprasong N, [Cauchemez S](#), Schweizer HP, Razafimandimby H, Rogier C, Rajerison M. Transmission of antimicrobial resistant *Yersinia pestis* during a pneumonic plague outbreak. *Clinical Infectious Diseases* 2021; 9:ciab606.
94. Gaymard A, Bosetti P, Feri A, Destras G, Enouf V, Andronico A, Burrel S, Behillil S, Sauvage C, Bal A, Morfin F, Van Der Werf S, Josset L, ANRS MIE AC43 COVID-19, French viro COVID group, Blanquart F, Coignard B*, [Cauchemez S*](#), Lina B*. Early assessment of diffusion and possible expansion of SARS-CoV-2 lineage 201/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021. *Eurosurveillance* 2021; 9. * Equal contribution.

95. Travier L, Alonso M, Andronico A, Hafner L, Disson O, Lledo PM, [Cauchemez S](#), Lecuit M. Neonatal susceptibility to meningitis results from the immaturity of epithelial barriers and gut microbiota. *Cell Rep* 2021; 35:109319.
96. Salje H, Alera MT, Chua MN, Hunsawong T, Ellison D, Srikiatkachorn A, Jarman RG, Gromowski GD, Rodriguez-Barraquer I, [Cauchemez S](#), Cummings DAT, Macareo L, Yoon IK, Fernandez S, Rothman A. Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection. *Nature Medicine* 2021; 27:1395-1400.
97. Landier J, Paireau J, Rebaudet S, Legendre E, Lehot L, Fontanet A, [Cauchemez S](#), Gaudart J. Cold and dry winter conditions are associated with greater SARS-CoV-2 transmission at regional level in western countries during the first epidemic wave. *Sci Rep* 2021; 11:12756.
98. Galmiche S, Charmet T, Schaeffer L, Paireau J, Grant R, Chény O, Von Platen C, Maurizot A, Blanc C, Dinis A, Martin S, Omar F, David C, Septfons A, [Cauchemez S](#), Carrat F, Mailles A, Levy-Bruhl D, Fontanet A. Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study. *Lancet Reg Health Eur* 2021; 7:100148.
99. Layan M, Dellicour S, Baele G, [Cauchemez S](#)*, Bourhy H*. Mathematical modelling and phylodynamics for the study of dog rabies dynamics and control: A scoping review. *PLoS NTD* 2021; 15:e0009449. * Equal contribution.
100. Wei XL, Yang J, Gao LD, Wang LL, Liao QH, Qiu Q, Luo KW, Yu SB, Zhou YH, Liu FF, Chen Q, Zhang JJ, Dai BB, Yang H, Zhou JX, Xing WJ, Chen XH, He M, Ren LS, Guo JX, Luo L, Wu P, Chen ZY, van Doorn HR, [Cauchemez S](#), Cowling BJ, Yu HJ. The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother-neonate cohort study. *Lancet Infectious Diseases* 2021; 3:418-426.
101. Kengne-Nde C, Tejiokem MC, Orne-Gliemann J, Melingui B, Koki Ndombo P, Essounga NA, Bissek AC, [Cauchemez S](#), Tchendjou PT. Couple Oriented counselling improves male partner involvement in sexual and reproductive health of a couple: Evidence from the ANRS PRENAHTEST randomized trial. *PLoS One* 2021; 16: e0255330.
102. O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, Fontanet A, [Cauchemez S](#)*, Salje H*. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature* 2020; doi.org/10.1038/s41586-020-2918-0. * Equal contribution.
103. [Cauchemez S](#), Kiem Tran C, Paireau J, Rolland P, Fontanet A. Lockdown impact on COVID-19 epidemics in regions across metropolitan France. *Lancet* 2020; 396:1068-1069.
104. Fontanet A, [Cauchemez S](#). COVID-19 herd immunity : where are we? *Nature Reviews Immunology* 2020; 10:583-584.
105. Adam DC, Wu P, Wong JY, Lau EHY, Tsang TK, [Cauchemez S](#), Leung GM, Cowling BJ. Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. *Nature Medicine* 2020 ; doi : 10.1038.
106. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, Andronico A, Hoze N, Richet J, Dubost CL, Le Start Y, Lessler J, Levy Bruhl D, Fontanet A, Opatowski L, Boelle PY, [Cauchemez S](#). Estimating the burden of SARS-CoV-2 in France. *Science* 2020; 369:208.
107. Hoze N, Salje H, Rousset D, Fritzell C, Vanhomwegen J, Bailly S, Najm M, Enfissi A, Manuguerra JC, Flamand C, [Cauchemez S](#). Reconstructing Mayaro virus circulation in French Guiana shows frequent spillovers. *Nature Communications* 2020; 11:2842.
108. Nikolay B, Salje H, Khan AKMD, Sazzad HMS, Satter SM, Rahman M, Doan S, Knust B, Flora MS, Luby SP, [Cauchemez S](#)*, Gurley ES*. A framework to monitor changes in transmission and epidemiology of emerging pathogens: lessons from Nipah virus. *JID* 2020; 221:S363-S369. * Equal contribution
109. Du Z, Wang L, [Cauchemez S](#), Xu X, Wang X, Cowling BJ, Meyers LA. Risk for transportation of 2019 novel coronavirus disease from Wuhan to other cities in China. *Emerging Infectious Diseases* 2020; 26:1049-1052.
110. Metcalf CJE, Wesolowski A, Winter AK, Lessler J, [Cauchemez S](#), Moss WJ, McLean AR, Grenfell BT. Using serology to anticipate measles post-honeymoon period outbreaks. *Trends Microbiol* 2020; 28:597-600.
111. Razafimahatratra SL, Wesolowski A, Rafetrarivony L, Heraud JM, Jones FK, [Cauchemez S](#), Razafindratsimandresy R, Raharinantoanina SJ, Harimanana A, Collard JM, Metcalf CJE. Seroprevalence of pertussis in Madagascar and implications for vaccination. *Epidemiology and infection* 2020; 148:e283.
112. Kraemer MUG, Pigott DM, Hill SC, Vanderlott S, Reiner RC Jr, Stasse S, Brownstein JS, Gutierrez B, Dennig F, Hay SI, Wint GRW, Pybus OG, Castro MC, Vinck P, Pham PN, Nilles EJ, [Cauchemez S](#). Dynamics of conflict during the Ebola outbreak in the Democratic Republic of the Congo 2018-2019. *BMC Med* 2020; 18:113.
113. Diarra I, Nurtop E, Sangare AK, Sagara I, Pastorino B, Sacko S, Zeguime A, Coulibaly D, Fofana B, Gallian P, Priet S, Drexler JF, Failloux AB, Dabo A, Thera MA, Djimde A, Kouriba B, [Cauchemez S](#), de Lamballerie X, Hoze N, Doumbo OK. Zika virus circulation in Mali. *Emerging Infectious Diseases* 2020; 26:945-952.
114. Lee KH, Nikolay B, Sazzad HMS, Hossain MJ, Khan AKMD, Rahman M, Satter SM, Nichol ST, Klena JD, Pulliam JRC, Kilpatrick AM, Sultana S, Afroj S, Daszak P, Luby S, [Cauchemez S](#), Salje H, Gurley E. Changing contact patterns over disease progression: Nipah virus as a case study. *JID* 2020; online publication.
115. Pellis L, [Cauchemez S](#), Ferguson NM, Fraser C. Systematic selection between age and household structure for models aimed at emerging epidemic predictions. *Nature Communications* 2020; 11:906.
116. Sow A, Nikolay B, Faye O, [Cauchemez S](#), Cano J, Diallo M, Faye O, Sadio B, Ndiaye O, Weaver SC, Dia AT, Sall AA, Malvy D. Changes in the transmission dynamic of chikungunya virus in Southeastern Senegal. *Viruses* 2020; 12:196.
117. Nguyen-Van-Tam JS, Killingley B, Enstone J, Hewitt M, Pantelic J, Grantham ML, de Mesquita PJB, Lambkin-Williams R, Gilbert A, Mann A, Forni J, Noakes CJ, Levine MZ, Berman L, Lindstrom S, [Cauchemez S](#), Bischoff W, Tellier R, Milton DK. Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment. *PLoS Pathogens* 2020; 16: e1008704.
118. Capai L, Hoze N, Chiaroni J, Gross S, Djoudi R, Charrel R, Izopet J, Bosseur F, Priet S, [Cauchemez S](#), de Lamballerie X, Falchi A, Gallian P. Seroprevalence of hepatitis E virus among blood donors on Corsica, France, 2017. *Eurosurveillance* 2020; 25:1900336.
119. Chen J, hu H, Horby PW, Wang Q, Zhou J, Jiang H, Liu L, Zhang T, Zhang Y, Chen X, Deng X, Nikolay B, Wang W, [Cauchemez S](#), Guan Y, Uyeki TM, Yu H. Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans. *J Infect* 2020; 80:310-319.
120. Besombes C, Njouom R, Paireau J, Lachenal G, Texier G, Tejiokem M, [Cauchemez S](#), Pépin J, Fontanet A. The epidemiology of hepatitis delta virus infection in Cameroon. *Gut* 2020; 69:1294-1300.
121. Cousien A, Ledien J, Souv K, Leang R, Huy R, Fontenille D, Ly S, Duong V, Dussart P, Piola P*, [Cauchemez S](#)*, Tarantola A*. Predicting dengue outbreaks in Cambodia. *Emerging Infectious Diseases* 2019; 25:2281-2283. * Equal contribution.
122. Nikolay B, Salje H, Hossain MJ, Khan AKMD, Sazzad HMS, Rahman M, Daszak P, Stroher U, Pulliam JRC, Kilpatrick AM, Nichol ST, Klena JD, Sultana S, Afroj S, Luby SP, [Cauchemez S](#)*, Gurley ES*. Transmission of Nipah Virus-14 Years of Investigations in Bangladesh. *New England Journal of Medicine* 2019; 380:1804-1814. * Equal contribution.
123. Randremanana R, Andrianavaorimanana V, Nikolay B, Ramasindrazana B, Paireau J, ten Bosch QA, Rakotondramanga JM, Rahajandraibe S, Rahelinirina S, Rakotomanana F, Rakotoarimanana FM, Randriamampionona LB, Razafimbiana V, Randria MJDD, Raberahona M, Mikaty G, Le Guern AS, Rakotonjanabelo LA, Ndiaye CF, Rasolofo V, Bertherat E*, Ratsitorahina M*,

Cauchemez S^{*,} Baril L^{*}, Spiegel A^{*}, Rajerison M^{*}. Epidemiological characteristics of an urban plague epidemic in Madagascar, August–November, 2017: an outbreak report. *Lancet Infectious Diseases* 2019; 19:537-545. ^{*} Equal contribution, ⁺ Corresponding author.

124. Cousien A, Abel S, Monthieux A, Andronico A, Calmont I, Cervantes M, Césaire R, Gallian P, de Lamballerie X, Laouénan C, Salje H, ten Bosch QA, Cabié A, Cauchemez S. Assessing Zika virus transmission within households during an outbreak in Martinique, 2015-2016. *American Journal of Epidemiology* 2019; online publication.
125. Andronico A, Courcoul A, Bronner A, Scoizec A, Lebouquin-Lenevey S, Guinat C, Paul MC, Durand B, Cauchemez S. Highly pathogenic avian influenza H5N8 in south-west France 2016-2017: A modeling study of control strategies. *Epidemics* 2019; online publication.
126. Cauchemez S, Hoze N, Cousien A, Nikolay B, ten Bosch Q. How modelling can enhance the analysis of imperfect epidemic data. *Trends in parasitology* 2019; 5:369-379.
127. Flamand C, Bailly S, Fritzell C, Berthelot L, Vanhomwegen J, Salje H, Paireau J, Matheus S, Enfissi A, Fernandes-Pellerin S, Djossou F, Linares S, Carod JF, Kazanji M, Manuguerra JC, Cauchemez S, Rousset D. Impact of zika virus emergence in French Guiana: a large general population seroprevalence survey. *Journal of Infectious Diseases* 2019; 12:1915-1925.
128. Thompson RN, Stockwin JE, van Gaalen RD, Polonsky JA, Kamvar ZN, Demarsh PA, Dahlqvist E, Li S, Miguel E, Jombart T, Lessler J, Cauchemez S, Cori A. Improved inference of time-varying reproduction numbers during infectious disease outbreaks. *Epidemics* 2019; 29:100356.
129. Donnelly CA, Malik MR, Elkholy A, Cauchemez S, Van Kerkhove MD. Worldwide reduction in MERS cases and deaths since 2016. *Emerging Infectious Diseases* 2019; 25:1758-1760.
130. Bernard-Stoecklin S, Nikolay B, Assiri A, Bin Saeed AA, Ben Embarek PK, El Bushra H, Ki M, Malik MR, Fontanet A, Cauchemez S, Van Kerkhove MD. Comparative Analysis of Eleven Healthcare-Associated Outbreaks of Middle East Respiratory Syndrome Coronavirus (Mers-Cov) from 2015 to 2017. *Scientific Reports* 2019; 9:7385.
131. Courtejoie N, Cauchemez S, Zanella G, Durand B. A network-based approach to modelling bluetongue spread in France. *Preventive Veterinary Medicine* 2019; 170:104744.
132. Kraemer MUG, Reiner RC, Brady OJ, Messina JP, Gilbert M, Pigott DM, Yi D, Johnson K, Earl L, Marczak LB, Shirude S, Weaver ND, Bisanzio D, Perkins TA, Lai S, Lu X, Jones P, Coelho GE, Carvalho RG, Van Bortel W, Marsboom C, Hendrickx G, Schaffner F, Moore CG, Nax HH, Bengtsson L, Wetter E, Tatem AJ, Brownstein JS, Smith DL, Lambrechts L, Cauchemez S, Linard C, Faria NR, Pybus OG, Scott TW, Liu O, Yu H, Wint GRW, Hay SI, Golding N. Past and future spread of the arbovirus vectors *Aedes aegypti* and *Aedes albopictus*. *Nature Microbiology* 2019; 4:854-863.
133. Tsang T, Fang VJ, Ip DKM, Perera RAPM, So HC, Leung GM, Peiris JSM, Cowling BJ, Cauchemez S. Indirect protection from vaccinating children against influenza in households. *Nature Communications* 2019; 10:106.
134. Churakov M, Villabona-Arenas CJ, Kraemer MUG, Salje H, Cauchemez S. Spatio-temporal dynamics of dengue in Brazil: Seasonal travelling waves and determinants of regional synchrony. *PLoS NTD* 2019; 13:e0007012.
135. Mitchell PK, Mier-Y-Teran-Romero L, Biggerstaff BJ, Delorey MJ, Aubry M, Cao-Lormeau VM, Lozier MJ, Cauchemez S, Johansson MA. Reassessing Serosurvey-Based Estimates of the Symptomatic Proportion of Zika Virus Infections. *AJE* 2019; 188:206-213.
136. Demeure CE, Derbise A, Guillas C, Gerke C, Cauchemez S, Carniel E, Pizarro-Cerdá J. Humoral and cellular immune correlates of protection against bubonic plague by a live *Yersinia pseudotuberculosis* vaccine. *Vaccine* 2019; 37:123-129.
137. Salje H, Cummings DAT, Rodriguez-Barraquer I, Katzelnick LC, Lessler J, Klungthong C, Thaisomboonsuk B, Nisalak A, Weg A, Ellison D, Macareo L, Yoon IK, Jarman R, Thomas S, Rothman AL, Endy T, Cauchemez S. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. *Nature* 2018; 557: 719-723.
138. Faria NR, Kraemer MUG, Hill SC, Goes de Jesus J, Aguiar RS, Iani FCM, Xavier J, Quick J, du Plessis L, Dellicour S, Thézé J, Carvalho RDO, Baele G, Wu CH, Silveira PP, Arruda MB, Pereira MA, Pereira GC, Lourenço J, Obolski U, Abade L, Vasylyeva TI, Giovanetti M, Yi D, Weiss DJ, Wint GRW, Shearer FM, Funk S, Nikolay B, Fonseca V, Adelino TER, Oliveira MAA, Silva MVF, Sacchetto L, Figueiredo PO, Rezende IM, Mello EM, Said RFC, Santos DA, Ferraz ML, Brito MG, Santana LF, Menezes MT, Brindeiro RM, Tanuri A, dos Santos FCP, Cunha MS, Nogueira JS, Rocco IM, da Costa AC, Komninakis SCV, Azevedo V, Chieppe AO, Araújo ESM, Mendonça MCL, dos Santos CC, dos Santos CD, Mares-Guia AM, Nogueira RMR, Sequeira PC, Abreu RG, Garcia MHO, Abreu AL, Okumoto O, Kroon EG, de Albuquerque CFC, Lewandowski K, Pullan ST, Carroll M, de Oliveira T, Sabino EC, Souza RP, Suchard MA, Lemey P, Trindade GS, Drumond BP, Filippis AMB, Loman NJ, Cauchemez S^{*}, Alcantara LCJ^{*}, Pybus OG^{*}. Genomic and epidemiological monitoring of yellow fever virus transmission potential. *Science* 2018; 361:894-899. ^{*}: Equal contribution.
139. Tarantola A, Ly S, Chan M, In S, Peng Y, Hing C, Taing CN, Phoen C, Ly S, Cauchemez S, Buchy P, Dussart P, Bourhy H, Mary JY. Intradermal rabies post-exposure prophylaxis can be abridged with no measurable impact on clinical outcome in Cambodia, 2003-2014. *Vaccine* 2018; online publication.
140. Kraemer MUG, Cummings DAT, Funk S, Reiner RC, Faria NR, Pybus OG, Cauchemez S. Reconstruction and prediction of viral disease epidemics. *Epidemiology and Infection* 2018; online publication.
141. O'Reilly KM, Lowe R, Edmunds WJ, Mayaud P, Kucharski A, Eggo RM, Funk S, Bhatia D, Khan K, Kraemer MUG, Wilder-Smith A, Rodrigues LC, Brasil P, Massad E, Jaenisch T, Cauchemez S, Brady OJ, Yakob L. Projecting the end of the Zika virus epidemic in Latin America: a modelling analysis. *BMC Medicine* 2018; 16: 180.
142. Cauchemez S, Bourhy H. Comment: Improving the provision of rabies post-exposure prophylaxis. *Lancet Infectious Disease* 2018; online publication.
143. Winter AK, Wesolowski AP, Mensah KJ, Ramamonjharisoa MB, Randriamanantena AH, Razafindratsimandresy R, Cauchemez S, Lessler J, Ferrari MJ, Metcalf CJE, Heraud JM. Revealing Measles Outbreak Risk With a Nested Immunoglobulin G Serosurvey in Madagascar. *American Journal of Epidemiology* 2018; 187(10):2219-2226.
144. Ihantamalala FA, Herbreteau V, Rakotoarimanana FMJ, Rakotondramanga JM, Cauchemez S, Rahoilijaona B, Pennober G, Buckee CO, Rogier C, Metcalf CJE, Wesolowski A. Estimating sources and sinks of malaria parasites in Madagascar. *Nature Communications* 2018; 9:3897.
145. Nikolay B, Cauchemez S. Perspective : Enterovirus outbreak dynamics. *Science* 2018; online publication.
146. Paireau J, Pelat C, Caserio-Schönemann C, Pontais I, Le Strat Y, Lévy-Bruhl D, Cauchemez S. Mapping influenza activity in emergency departments in France using Bayesian model-based geostatistics. *Influenza and Other Respiratory Viruses* 2018; online publication.
147. Courtejoie N, Salje H, Durand B, Zanella G, Cauchemez S. Using serological studies to reconstruct the history of bluetongue epidemics in French cattle under successive vaccination campaigns. *Epidemics* 2018; 25:54-60.
148. Succo T, Noël H, Nikolay B, Maquart M, Cochet A, Leparc-Goffart I, Catelinois O, Salje H, Pelat C, de Crouy-Chanel P, de Valk H, Cauchemez S, Rousseau C. Dengue serosurvey after a 2-month long outbreak in Nîmes, France, 2015: was there more than met the eye? *Eurosurveillance* 2018; 23.

149. Cortes MC, Cauchemez S, Lefrancq N, Luby SP, Hossain MJ, Sazzad HMS, Rahman M, Daszak P, Salje H, Gurley ES. Characterization of the spatial and temporal distribution of Nipah virus spillover events in Bangladesh, 2007-2013. *Journal of Infectious Diseases* 2018; 217:1390-1394.
150. Sheikh Taslim Ali, Wu P, Cauchemez S, He D, Fang VJ, Cowling BJ, Tian L. Ambient ozone and influenza transmissibility in Hong Kong. *European Respiratory Journal* 2018; 51: online publication.
151. Ihantamalala FA, Rakotoarimanana FMJ, Ramiadantsoa T, Rakotondramanga JM, Pennober G, Rakotomanana F, Cauchemez S, Metcalf CJE, Herbreteau V, Wesolowski A. Spatial and temporal dynamics of malaria in Madagascar. *Malaria Journal* 2018; online publication.
152. Flamand C, Fritzell C, Matheus S, Dueymes M, Carles G, Favre A, Enfissi A, Adde A, Demar M, Kazanji M, Cauchemez S*, Rousset D*. The proportion of asymptomatic infections and spectrum of disease among pregnant women infected by Zika virus: systematic monitoring in French Guiana, 2016. *Eurosurveillance* 2017; 22: 23-31. *: Equal contribution.
153. Faria NR, Quick J, Claro IM, Theze J, de Jesus JG, Giovanetti M, Kraemer MUG, Hill SC, Black A, da Costa AC, Franco LC, Silva SP, Wu CH, Raghwanji J, Cauchemez S, du Plessis L, Verotti MP, de Oliveira WK, Carmo EH, Coelho GE, Santelli ACFS, Vinhal LC, Henriques CM, Simpson JT, Loose M, Andersen KG, Grubaugh ND, Somasekar S, Chiu CY, Munoz-Medina JE, Gonzalez-Bonilla CR, Arias CF, Lewis-Ximenez LL, Baylis SA, Chieppe AO, Aguiar SF, Fernandes CA, Lemos PS, Nascimento BLS, Monteiro HAO, Siqueira IC, de Queiroz MG, de Souza TR, Bezerra JF, Lemos MR, Pereira GF, Loudal D, Moura LC, Dhalia R, Franca RF, Magalhaes T, Marques ET, Jaenisch T, Wallau GL, de Lima MC, Nascimento V, de Cerqueira EM, de Lima MM, Mascarenhas DL, Neto JPM, Levin AS, Tozetto-Mendoza TR, Fonseca SN, Mendes-Correa MC, Milagres FP, Segurado A, Holmes EC, Rambaut A, Bedford T, Nunes MRT, Sabino EC, Alcantara LCJ, Loman NJ, Pybus OG. Establishment and cryptic transmission of Zika virus in Brazil and the Americas. *Nature* 2017; 645:406-+.
154. Andronico A, Dorléans F, Fergé JL, Salje H, Ghawché F, Signate A, Daudens-Vaysse E, Baudouin L, Dub T, Aubry M, Cao-Lormeau VM, Ledrans M, Noel H, Mallet HP, Fontanet A, Cabié A, Cauchemez S. Real-Time Assessment of Health-Care Requirements During the Zika Virus Epidemic in Martinique. *American Journal of Epidemiology* 2017; 15:1-10.
155. Nikolay N, Salje H, Sturm-Ramirez K, Azziz-Baumgartner E, Homaira N, Ahmed M, Iuliano AD, Paul RC, Rahman M, Hossain MJ, Luby SP, Cauchemez S*, Gurley E*. Evaluating hospital-based surveillance for outbreak detection in Bangladesh: analysis of healthcare utilization data. *PLoS Medicine* 2017; 14:e1002218. *: Equal contribution.
156. Kraemer MUG, Faria NR, Reiner Jr RC, Golding N, Nikolay B, Stasse S, Johansson MA, Salje H, Faye O, Wint GRW, Niedrig M, Shearer FM, Hill SC, Thompson RN, Bisanzio D, Taveira N, Nax HH, Pradelski BSR, Nsoesie EO, Murphy NR, Bogoch II, Khan K, Brownstein JS, Tatem AJ, de Oliveira , Smith DL, Sall A, Pybus OG, Hay SI, Cauchemez S. Spread of Yellow Fever Virus outbreak in Angola and the Democratic Republic Congo 2015-16: a modelling study. *Lancet Infectious Diseases* 2017; 17:330-338.
157. Salje H, Lessler J, Paul KK, Azman AS, Rahman MW, Rahman M, Cummings D, Gurley ES, Cauchemez S. How social structures, space and behaviours shape the spread of infectious diseases using chikungunya as a case study. *PNAS* 2016; 113:13420-13425.
158. Cauchemez S, Nouvellet P, Cori A, Jombart T, Garske T, Clapham H, Moore S, Mills HL, Salje H, Collins C, Rodriguez-Barraquer I, Riley S, Truelove S, Algarni H, Hakkeem R, AlHarbi K, Turkistani A, Aguas R, Cummings D, Van Kerkhove MD, Donnelly C, Lessler J, Fraser C, Al-Barrak A, Ferguson NM. Unraveling the drivers of MERS-CoV transmission. *PNAS* 2016; 113:9081-9086.
159. Cauchemez S, Besnard M, Garel C, Fontanet A, Mallet HP. Correspondence – Could clinical symptoms be a predictor of complications in Zika infection? *The Lancet* 2016; 388:338-339.
160. Cauchemez S, Besnard M, Bompard P, Dub T, Guilmotte-Arthur P, Eyrolle-Guignot D, Salje H, Van Kerkhove MD, Abadie V, Garel C, Fontanet A, Mallet HP. Association between Zika virus and microcephaly in French Polynesia, 2013-2015: a retrospective study. *The Lancet* 2016; 387:2125-32.
161. Imai N, Dorigatti I, Cauchemez S, Ferguson NM. Estimating dengue transmission intensity from case-notification data from multiple countries. *PLoS NTD* 2016; 10:e0004833.
162. Salje S, Cauchemez S, Alera MT, Rodriguez-Barraquer I, Thaisomboonsuk B et al. Reconstruction of 60 Years of Chikungunya Epidemiology in the Philippines Demonstrates Episodic and Focal Transmission. *The Journal of Infectious Diseases* 2016; 213: 604-10.
163. Fumanelli L, Ajelli M, Merler S, Ferguson NM, Cauchemez S. Model-based comprehensive analysis of school closure policies for mitigating influenza epidemics and pandemics. *PLoS Comp Biol* 2016; 12(1):e1004681.
164. Horwood PF, Andronico A, Tarantola A, Salje H, Duong V, Mey C, Ly S, Dussart P, Cauchemez S, Buchy P. Seroepidemiology of human enterovirus 71 infection among children, Cambodia. *Emerging Infectious Diseases* 2016; 22:92-95.
165. Tsang TK, Fang VJ, Perera RAPM, Ip DKM, Leung GM, Peiris JSM, Cauchemez S*, Cowling BJ*. Interpreting seroepidemiologic studies of influenza in a context of nonbracketing sera. *Epidemiology* 2016; 27:152-158. * Equal contribution, + Corresponding author.
166. Tsang TK, Fang VJ, Chan KH, Ip DKM, Leung GM, Peiris JSM, Cowling BJ, Cauchemez S. Individual correlates of infectivity of influenza A virus infections in households. *Plos One* 2016; 11:e0154418.
167. Lessler J, Salje H, Van Kerkhove MD, Ferguson NM, Cauchemez S, Rodriguez-Barraquer I, Hakeem R, Jombart T, Aguas R, Al-Barrak A, Cummings DAT. Estimating the severity and subclinical burden of Middle East Respiratory Syndrome Coronavirus infection in the Kingdom of Saudi Arabia. *American Journal of Epidemiology* 2016; 183:657-663.
168. Bourhy H, Nakoune E, Hall M, Nouvellet P, Lepelletier A, Talbi C, Watier L, Holmes EC, Cauchemez S, Lemey P, Donnelly CA, Rambaut A. Revealing the micro-scale signature of endemic zoonotic disease transmission in an African urban setting. *PLoS Pathogens* 2016; 12:e1005525.
169. Tsang TK, Lau LLH, Cauchemez S, Cowling BJ. Household transmission of influenza virus. *Trends in Microbiology* 2016; 24:123-133.
170. Hem S, Ly S, Votsi I, Vogt F, Asgari N, Buchy P, Heng S, Picardeau M, Sok T, Ly S, Huy R, Guillard B, Cauchemez S, Tarantola A. Estimating the Burden of Leptospirosis among Febrile Subjects Aged below 20 Years in Kampong Cham Communities, Cambodia, 2007-2009. *PLoS One* 2016; 11:e0151555.
171. Freeman G, Perera RAPM, Ngan E, Fang VJ, Cauchemez S, Ip DKM, Peiris JSM, Cowling BJ. Quantifying homologous and heterologous antibody titre rises after influenza virus infection. *Epidemiology and Infection* 2016; 144:2306-2316.
172. Killingley B, Greateorex J, Digard P, Wise H, Garcia F, Varsani H, Cauchemez S, Enstone JE, Hayward A, Curran MD, Read RC, Lim WS, Nicholson KG, Nguyen-Van-Tam JS. The environmental deposition of influenza virus from patients infected with influenza A(H1N1)pdm09: Implications for infection prevention and control. *Journal of Infection and Public Health* 2016; 9:278-288.
173. Faye O, Andronico A, Faye O, Salje H, Boëlle PY, Magassouba NF, Bah EI, Koivogui L, Diallo B, Diallo AA, Keita S, Konde MK, Fowler R, Fall G, Cauchemez S*, Sall AA*. Use of Viremia to Evaluate the Baseline Case Fatality Ratio of Ebola Virus Disease and Inform Treatment Studies: A Retrospective Cohort Study. *PLoS Medicine* 2015; 12(12): e1001908. * Equal contribution, +Corresponding author.
174. Faye O, Boëlle PY, Heleze E, Faye O, Loucoubar C, Magassouba NF, Soropogui B, Keita S, Gakou T, Bah EHI, Koivogui, Sall AA, Cauchemez S. Chains of transmission and control of Ebola virus disease in Conakry, Guinea, in 2014: an observational study. *Lancet Infectious Diseases* 2015; 15: 320-326.

175. Tsang TK, Cowling BJ, Fang VJ, Chan KH, Ip DKM, Leung GM, Peiris M, Cauchemez S. Influenza A virus shedding and infectivity in households. *Journal of Infectious Diseases* 2015; 212:1420-1428.
176. Gambhir M, Clark TA, Cauchemez S, Tartof SY, Sverdlow DL, Ferguson NM. A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States. *PLoS Computational Biology* 2015; 11: e1004138.
177. Imai N, Dorigatti I, Cauchemez S, Ferguson NM. Estimating dengue transmission intensity from sero-prevalence surveys in multiple countries. *PLoS NTD* 2015; 9:e0003719.
178. Walker PG, Jost C, Ghani AC, Cauchemez S, Bett B, Azhar M, Murahman J, Widiastuti T, Daju D, Mariner J. Estimating the Transmissibility of H5N1 and the Effect of Vaccination in Indonesia. *Transbound Emerg Dis* 2015; 62:200-208.
179. Mansiaux Y, Salez N, Lapidus N, Setbon M, Adreoletti L, Leruez-Ville M, Cauchemez S, Gougeon ML et al. Causal analysis of H1N1pdm09 influenza infection risk in a household cohort. *Journal of Epidemiology and Community Health* 2015; 69:272-277.
180. Tong SYC, Holden MTG, Nickerson EK, Cooper BS, Koser CU, Cori A, Jombart T, Cauchemez S, Fraser C et al. Genome sequencing defines phylogeny and spread of methicillin-resistant *Staphylococcus aureus* in a high transmission setting. *Genome Research* 2015; 25: 111-118.
181. Xu CL, Chan KH, Tsang TK, Fang VJ, Fung ROP, Ip DKM, Cauchemez S, Leung GM, Peiris JSM, Cowling BJ. Comparative Epidemiology of Influenza B Yamagata- and Victoria-Lineage Viruses in Households. *American Journal of Epidemiology* 2015; 182:705-713.
182. Iyengar P, von Mollendorf C, Tempia S, Moerdyk A, Valley-Omar Z, Hellferscee O, Martinson N, Chhagan M, McMorro M, Gambhir M, Cauchemez S, Variava E, Masonoke K, Cohen AL, Cohen C. Case-ascertained study of household transmission of seasonal influenza - South Africa, 2013. *The journal of infection* 2015; 71:578-86.
183. Churcher TS, Cohen JM, Novotny J, Ntshalintshali N, Kunene S, Cauchemez S. Measuring the path toward malaria elimination. *Science* 2014; 1230: 1230-1232.
184. Cauchemez S, Ferguson NM, Fox A, Mai LQ, Thanh LT, Thai PQ, Thoang DD, Duong TN, Hoa LNM, Hien NT, Horby P. Determinants of influenza transmission in South East Asia : Insights from a household cohort study in Vietnam. *PLoS Pathogens* 2014; 10(8) : e1004310.
185. Pelat C, Ferguson NM, White PJ, Reed C, Finelli L, Cauchemez S*, Christophe Fraser*. Optimizing the precision of case fatality ratio estimates under the surveillance pyramid approach. *American Journal of Epidemiology* 2014; 180:1036-1046. * Equal contribution.
186. Cauchemez S, Ledrans M, Poletto C, Quenel P, de Valk H, Colizza V, Boëlle PY. Local and regional spread of chikungunya fever in the Americas. *Eurosurveillance* 2014; 19:15-23.
187. Cauchemez S, Fraser C, Van Kerkhove M, Donnelly C, Riley S, Rambaut A, Enouf V, van der Werf S, Ferguson NM. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. *The Lancet Infectious Diseases* 2014; 1:50-56.
188. Cauchemez S, Van Kerkhove MD, Archer BN et al. School closures during the 2009 influenza pandemic: national and local experiences. *BMC Infect Dis* 2014; 14.
189. Tsang TK, Cauchemez S, Perera RAPM, Freeman G, Fang VJ, Ip DKM, Leung GM, Peris JSM, Cowling BJ. Association between antibody titers and protection against influenza virus infection within households. *Journal of Infectious Diseases* 2014; 210:684-692.
190. Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic and zoonotic influenza: a systematic review of the literature. *BMC Infectious Diseases* 2014; 14:480.
191. Jombart T, Cori A, Didelot X, Cauchemez S, Fraser C, Ferguson NM. Bayesian Reconstruction of Disease Outbreaks by Combining Epidemiologic and Genomic Data. *PLoS Computational Biology* 2014; 10:e1003457.
192. Cauchemez S, Epperson S, Biggerstaff M, Sverdlow D, Finelli L, Ferguson NM. Using Routine Surveillance Data to Estimate the Epidemic Potential of Emerging Zoonoses: Application to the Emergence of US Swine Origin Influenza A H3N2v Virus. *Plos Medicine* 2013; e1001399.
193. Dorigatti I, Cauchemez S, Ferguson NM. Increased transmissibility explains the third wave of infection by the 2009 H1N1 pandemic virus in England. *PNAS* 2013 ; 110 :13422-7.
194. Cori A, Ferguson NM, Fraser C, Cauchemez S. A new framework and software to estimate time-varying reproduction numbers during epidemics. *American Journal of Epidemiology* 2013; 178: 1505-1512.
195. Cauchemez S, Van Kerkhove M, Riley S, Donnelly C, Fraser C, Ferguson NM. Transmission scenarios for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and how to tell them apart. *Eurosurveillance* 2013; 18:7-13.
196. Gambhir M, Sverdlow DL, Finelli L, Van Kerkhove MD, Biggerstaff M, Cauchemez S, Ferguson NM. Multiple Contributory Factors to the Age Distribution of Disease Cases: A Modeling Study in the Context of Influenza A(H3N2v). *CID* 2013 ; 57 :S23-S27.
197. Nouvellet P, Donnelly CA, De Nardi M, Rhodes CJ, De Benedictis P, Citterio C, Obber F, Lorenzetto M, Pozza MD, Cauchemez S, Cattoli G. Rabies and canine distemper virus epidemics in the red fox population of northern Italy (2006-2010). *PLoS One* 2013. 8:e61588.
198. Lapidus N, de Lamballerie X, Salez N, Setbon M, Delabre RM, Ferrari P, Moyon N, Gougeon M-L, Vely F, Leruez-Ville M, Andreoletti L, Cauchemez S, Boelle P-Y, Vivier E, Abel L, Schwarzingen M, Legeas M, Le Cann P, Flahault A, Carrat F. Factors Associated with Post-Seasonal Serological Titer and Risk Factors for Infection with the Pandemic A/H1N1 Virus in the French General Population. *PLoS One* 2013.
199. Cauchemez S, Horby P, Fox A, Le Quynh M, Le Thi T et al. Influenza infection rates, measurement errors and the interpretation of paired serology. *PLoS Pathogens* 2012; 8(12): e1003061.
200. Yu H*, Cauchemez S*, Donnelly CA, Zhou L, Feng L, Xiang N et al. Transmission dynamics, border entry screening, and school holidays during the 2009 influenza A (H1N1) pandemic, China. *Emerg Infect Dis* 2012; 18:758-766. * Equal contribution.
201. Cauchemez S, Ferguson NM. Methods to infer transmission risk factors in complex outbreak data. *J R Soc Interface* 2012; 9:456-469.
202. Walker P, Cauchemez S, Hartemink N, Tiensin T, Ghani AC. Outbreaks of H5N1 in poultry in Thailand: the relative role of poultry production types in sustaining transmission and the impact of active surveillance in control. *J R Soc Interface* 2012; 9:1836-1845.
203. Dorigatti I, Cauchemez S, Pugliese A, Ferguson NM. A new approach to characterising infectious disease transmission dynamics from sentinel surveillance: Application to the Italian 2009-2010 A/H1N1 influenza pandemic. *Epidemics* 2012; 4:9-21.
204. Truscott J, Fraser C, Cauchemez S, Meeyai A, Hinsley W, Donnelly CA, Ghani A, Ferguson NM. Essential epidemiological mechanisms underpinning the transmission dynamics of seasonal influenza. *J R Soc Interface* 2012; 9:304-312.
205. Killingley B, Enstone JE, Greatorex J, Gilbert AS, Lambkin-Williams R, Cauchemez S, Katz JM, Booy R et al. Use of a Human Influenza Challenge Model to Assess Person-to-Person Transmission: Proof-of-Concept Study. *Journal of Infectious Diseases* 2012; 205:35-43.
206. Cremin I, Cauchemez S, Garnett GP, Gregson S. Patterns of uptake of HIV testing in sub-Saharan Africa in the pre-treatment era. *Trop Med Int Health* 2012; 17:e26-e37.

207. Lapidus N, de Lamballerie X, Salez N, Setbon M, Ferrari P, Delabre RM, Gougeon ML, Vely F, Leruez-Ville M, Andreoletti L, Cauchemez S, Boëlle PY, Vivier E, Abel L, Schwarzhinger M, Legeas M, Le Cann P, Flahault A, Carrat F. Integrative study of pandemic A/H1N1 influenza infections: design and methods of the CoPanFlu-France cohort. *BMC Public Health* 2012 ; 12:417.
208. Cauchemez S, Bhattarai A, Marchbanks TL, Fagan RP, Ostroff S, Ferguson NM, Swerdlow D, and the Pennsylvania H1N1 working group. Role of social networks in shaping disease transmission during a community outbreak of 2009 H1N1 pandemic influenza. *PNAS* 2011; 108:2825-2830.
209. Eggo R, Cauchemez S, Ferguson NM. Spatial dynamics of the 1918 influenza pandemic in England, Wales and the United States. *J R Soc Interface* 2011; 8:233-243.
210. Opatowski L, Fraser C, Griffin J, de Silva E, Van Kerkhove MD, Lyons EJ, Cauchemez S, Ferguson NM. Transmission Characteristics of the 2009 H1N1 Influenza Pandemic: Comparison of 8 Southern Hemisphere Countries. *PLoS Pathog* 2011; 7:e1002225.
211. Macintyre CR, Wang Q, Cauchemez S, Seale H, Dwyer DE, Yang P, Shi W, Gao Z et al. A cluster randomized clinical trial comparing fit-tested and non-fit-tested N95 respirators to medical masks to prevent respiratory virus infection in health care workers. *Influenza Other Respi Viruses* 2011; 5:170-179.
212. Donnelly C, Finelli L, Cauchemez S, Olsen SJ, Doshi S, Jackson ML, Kennedy ED, Kamimoto L et al. Serial Intervals and the Temporal Distribution of Secondary Infections within Households of 2009 Pandemic Influenza A (H1N1): Implications for Influenza Control Recommendations. *CID* 2011; 52(S1):S123-S130.
213. Marchbanks TL, Bhattarai A, Fagan RP, Ostroff S, Sodha SV, Moll ME, Lee BY, Chang CH, Ennis B, Britz P, Fiore A, Nguyen M, Palekar R, Archer WR, Gift TL, Leap R, Nygren BL, Cauchemez S, Angulo FJ, Swerdlow D, and the Pennsylvania Working Group. An Outbreak of 2009 Pandemic Influenza A (H1N1) Virus Infection in an Elementary School in Pennsylvania. *CID* 2011; 52(S1):S154-S160.
214. Lapidus N, de Lamballerie X, Salez N, Moyon N, Ferrari P, Gougeon ML, Vely F, Leruez-Ville M, Andreoletti L, Cauchemez S et al. Association between pandemic and seasonal influenza vaccination and haemagglutination antibody titers against A/H1N1v: a national representative survey in France, nested in the "Cohorts for Pandemic Influenza" (CoPanFlu - France). *Influenza and Other Respiratory Viruses* 2011; 5:180-183.
215. Walker P, Cauchemez S, Dah D, Pfeiffer D, Ghani A. A Bayesian approach to quantifying the effects of mass poultry vaccination upon the spatial and temporal dynamics of H5N1 in Northern Viet Nam. *Plos Comput Biol* 2010; 6:e1000683.
216. Killingley B, Grotorex J, Cauchemez S, Enstone JE, Curran M, Read RC, Lim WS, Hayward A, Nicholson KG, Nguyen-Van-Tam JS. Virus shedding and environmental deposition of novel A (H1N1) pandemic influenza virus: interim findings. *Health Technol Assess* 2010; 14(46):237.
217. Cremin I, Nyamukapa C, Sherr L, Hallett TB, Chawira G, Cauchemez S, Lopman B, Garnett GP et al. Patterns of Self-reported Behaviour Change Associated with Receiving Voluntary Counselling and Testing in a Longitudinal Study from Manicaland, Zimbabwe. *AIDS Behav* 2010; 14:708-715.
218. Cauchemez S, Donnelly CA, Reed C, Ghani AC, Fraser C, Kent CK, Finelli L, Ferguson NM. Household Transmission of 2009 Pandemic H1N1 influenza virus in the United States. *New England Journal of Medicine* 2009; 361:2619-27.
219. Cauchemez S, Ferguson NM, Wachtel C, Tegnell A, Saour G, Duncan B, Nicoll A. Closing schools during a pandemic: a review. *Lancet Infectious Disease* 2009; 9:473-81.
220. Lipsitch M, Riley S, Cauchemez S, Ghani AC, Ferguson NM. Managing and reducing uncertainty in an emerging influenza pandemic. *New England Journal of Medicine* 2009; 361:112-115.
221. Fraser C*, Donnelly CA*, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF et al. Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings. *Science* 2009; 324:1557-1561. * Equal contribution.
222. Evans D, Cauchemez S, Hayden FG. "Prepandemic" Immunization for Novel Influenza Viruses, "Swine Flu" Vaccine, Guillain-Barre Syndrome, and the Detection of Rare Severe Adverse Events. *Journal of Infectious Diseases* 2009; 200: 321-328.
223. Legrand J, Egan JR, Hall IM, Cauchemez S, Leach S, Ferguson NM. Estimating the Location and Spatial Extent of a Covert Anthrax Release. *Plos Comput Biol* 2009; 5.
224. Garske T, Legrand J, Donnelly CA, Ward H, Cauchemez S, Fraser C, Ferguson NM, Ghani AC. Assessing the severity of the novel influenza A/H1N1 pandemic, *BMJ* 2009; 339.
225. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF et al. Influenza: Making Privileged Data Public Response. *Science* 2009. 325:1072-1073.
226. MacIntyre CR, Cauchemez S, Dwyer DE, Seale H, Cheung P, Browne G, Fasher M, Wood JG et al. Effectiveness of face mask use to control respiratory virus transmission in households. *Emerging Infectious Diseases* 2009; 15:233-240.
227. Truscott J, Fraser C, Hinsley W, Cauchemez S, Donnelly C, Ghani A, Ferguson N. Quantifying the transmissibility of human influenza and its seasonal variation in temperate regions. *PLoS Curr Influenza* 2009; RRN1125.
228. Ghani AC, Baguelin M, Griffin J, Flasche S, Pebody R, van Hoek AJ, Cauchemez S, Hall IM et al. The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom. *PLoS Curr Influenza* 2009; RRN1130.
229. Cauchemez S, Valleron AJ, Boëlle PY, Flahault A, Ferguson NM. Estimating the impact of school closure on influenza transmission from Sentinel data. *Nature* 2008; 750-754.
230. Carrat F, Vergu E, Ferguson NM, Cauchemez S, Leach S, Valleron AJ. Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies. *American Journal of Epidemiology* 2008; 167:775-785.
231. Cauchemez S, Ferguson NM. Likelihood-based estimation of continuous-time epidemic models from time-series data: Application to measles transmission in London. *Journal of the Royal Society Interface* 2008; 5:885-897.
232. Cauchemez S, Temime L, Guillemot D, Varon E, Valleron AJ, Thomas G, Boëlle PY. Investigating heterogeneity in pneumococcal transmission: A Bayesian MCMC approach applied to a follow-up of schools. *Journal of the American Statistical Association* 2006; 101: 946-214.
233. Cauchemez S, Boëlle PY, Thomas G, Valleron AJ. Estimating in real-time the efficacy of control measures in emerging communicable diseases. *American Journal of Epidemiology* 2006; 164: 591-597.
234. Cauchemez S, Boëlle PY, Donnelly CA, Ferguson NM, Thomas G, Leung GM, Hedley AJ, Anderson RM, Valleron AJ. Real-Time Estimates in Early Detection of SARS. *Emerging Infectious Diseases* 2006; 12(1): 110-113.
235. Cauchemez S, Temime L, Valleron AJ, Varon E, Thomas G, Guillemot D, Boëlle PY. S. pneumoniae transmission according to inclusion in conjugate vaccines: Bayesian analysis of a longitudinal follow-up in schools. *BioMed Central Infectious Diseases* 2006; 6:14.
236. Carrat F, Lavenue A, Cauchemez S, Deleger S. Repeated influenza vaccination of healthy children and adults: borrow now, pay later? *Epidemiology and Infection* 2006; 63-70.
237. Ferguson NM, Cummings D, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke D. Strategies for containing an emerging influenza pandemic in SE Asia. *Nature* 2005; 437: 209-214.

238. Cauchemez S, Carrat F, Viboud C, Valleron AJ, Boëlle PY. A Bayesian MCMC approach to study transmission of influenza: Application to household longitudinal data. *Statistics in Medicine* 2004; 23(22):3469-3487.
239. Viboud C, Boëlle PY, Cauchemez S, Lavenu A, Valleron AJ, Flahault A., Carrat F. Risk factors of influenza transmission in households. *Brit J Gen Pract* 2004; 54(506):684-689.
240. Cauchemez S, Carrat F, Viboud C, Valleron AJ, Boëlle PY. Quantifying the role of children in influenza spread: an analysis of households follow-up. *Proceedings of the International Conference on Options for the Control of Influenza V Edited by Y. Kawaoka* 2004; 1263C:288-290.
241. Viboud C, Boëlle PY, Cauchemez S, Lavenu A, Valleron AJ, Flahault A., Carrat F. Risk factors of influenza transmission in households. *Proceedings of the International Conference on Options for the Control of Influenza V Edited by Y. Kawaoka* 2004; 1263C:291-294.
242. Cauchemez B, Extramiana F, Cauchemez S, Cosson S, Zouzou H, Meddane M, d'Allonnes LR, Lavergne T, Leenhardt A, Coumel P, Houdart E. High-flow perfusion of sheaths for prevention of thromboembolic complications during complex catheter ablation in the left atrium. *J Cardiovasc Electrophysiol* 2004; 15(3):276-83.

INVITED PRESENTATIONS

1. Cauchemez S. Studying the transmission of infectious diseases in a context of missing data. ANDCS conference, Paris, July 2025.
2. Cauchemez S. Modelling vector-borne diseases in the context of climate change. I3M conference, Strasbourg, March 2025.
3. Cauchemez S. The role of mathematical modelling to strengthen the interpretation of infectious disease surveillance data. Dakar Epidemics Forum, Dakar, December 2024.
4. Cauchemez S. Modelling the spread of emerging infectious diseases to support risk assessment and planning. Adapting to change: Emerging infectious diseases in a shifting climate, Paris, October 2024.
5. Cauchemez S. Using mathematical models to analyze epidemic data and gain key insights on epidemic dynamics and control. 3rd France-Japan symposium on HIV/AIDS and infectious diseases basic research, Paris, October 2024.
6. Cauchemez S. Deciphering the association between SARS-CoV-2 viral load and transmission from a large household transmission study in Nicaragua. Newton Institute, Cambridge, August 2024.
7. Cauchemez S. Challenges in estimating parameters and characterizing transmission dynamics from incomplete epidemic data. Rice conference, Paris, May 2024.
8. Cauchemez S. Using multiplex serology to study emerging pathogens: Challenges and opportunities. Determinants of dynamics of viral emergence and establishment in human populations, Princeton University, April 2024.
9. Cauchemez S. Using mathematical models to understand the spread of infectious diseases. The Future of Research on the Fusion of Humanities and Science: Toward the Realization of an Innovative Society, Kyoto, December 2023.
10. Cauchemez S. Using modelling to better understand infectious disease transmission dynamics. 10th i3S Annual Meeting, Porto, November 2023.
11. Cauchemez S. Modelling serological data to learn about infection and immunity. Individual and population immunity to respiratory viruses conference, Hong Kong, November 2023.
12. Cauchemez S. Challenges in estimating parameters and characterizing transmission dynamics from incomplete epidemic data. ModStatSAP, Paris, September 2023.
13. Cauchemez S. Forecasting COVID-19 healthcare demand: the case of France. CERP Modelling workshop, Lyon, June 2023.
14. Using mathematical models to analyze complex epidemic data and gain key insights on epidemic dynamics and control. Japan National Institute of Infectious Diseases, Tokyo, April 2023.
15. Cauchemez S. Using mathematical models to analyze complex epidemic data and gain key insights on epidemic dynamics and control. Japan National Institute of Infectious Diseases, Tokyo, April 2023.
16. Cauchemez S. How to best use serology for the surveillance of emerging infections. ECCMID, Copenhagen, April 2023.
17. Cauchemez S. Bayesian data augmentation methods applied to detailed outbreak data analysis. BaysComp, Finland, March 2023.
18. Cauchemez S. Statistical and mathematical methods to characterize infectious disease transmission from incomplete data. Ecole de l'INSERM Liliane Bettencourt, March 2023.
19. Cauchemez S. Evaluating the impact of school-based interventions during epidemics: Applications to influenza and COVID-19. Options XI for the control of influenza, Belfast, September 2022.
20. Cauchemez S. Public Health response to the pandemic. European meeting on HIV & hepatitis 2022, June 2022.
21. Cauchemez S. The impact of COVID-19 driven nonpharmaceutical interventions on the dynamics of the seasonal virus epidemics. Global Influenza Initiative, Annual meeting, November 2021.
22. Cauchemez S and Colizza V. Modelling COVID-19 to support the French pandemic response. Distinguished Lecture, International statistical approaches to COVID-19, The Alan Turing Institute, UK, October 2021.
23. Cauchemez S. Predictive models for epidemics : From influenza to COVID-19. Société Française d'Anesthésie et de Réanimation, Le Congrès, October 2021.
24. Cauchemez S. Anticipating the impact of vaccines on epidemic dynamics. International Conference « COVID-19, Advances and remaining challenges », Institut Pasteur, September 2021.
25. Cauchemez S. Round table - The Role of Data in the COVID-18 Pandemic. Leopoldina National Akademie der Wissenschaften, Germany, July 2021.
26. Cauchemez S. Estimating epidemic size and trajectories: Applications to SARS-CoV-2. VEO symposium, March 2021.
27. Cauchemez S. Modelling the spread of SARS-CoV-2 in France to support the management of the pandemic. Annual meeting of Labex IBEID, March 2021.
28. Cauchemez S. Modélisation de la COVID-19 et appui à la décision en santé publique. RICAI, Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse, December 2020.
29. Cauchemez S. Modelling to assess and anticipate the impact of the COVID-19 pandemic. Red Cross meeting, December 2020.
30. Cauchemez S. Modelling the spread of SARS-CoV-2 to support healthcare planning in France. Inception Annual Meeting, November 2020.
31. Cauchemez S. Analyse et modélisation de la pandémie de SARS-CoV-2 en France. Journées Statistique et Santé, Société Française de Biostatistique, October 2020.
32. Cauchemez S. Analyse et modélisation de la pandémie de SARS-CoV-2 en France. Characterizing the spread of SARS-CoV-2 in human populations. Journée François Jacob, Collège de France, September 2020.
33. Cauchemez S. Epidemic forecasting to support policy making. Statistical Methods for Post Genomic Data, Institut Pasteur, January 2020.

34. Cauchemez S. La modélisation comme outil d'aide à la préparation de la réponse aux épidémies émergentes. RICAI, Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse, December 2019.
35. Cauchemez S. Mathematical Modelling of Infectious Disease Epidemics. Inception annual meeting, November 2019.
36. Cauchemez S. Spread of pandemic influenza in US communities in 1920 and 2009: What changed in the last century? Options X for the control of influenza, Singapore, August 2019.
37. Cauchemez S. Risk assessment during infectious disease epidemics: from understanding to control. Pasteur Scientific Advisory Board, Paris, June 2019.
38. Cauchemez S. Dealing with imperfect diagnostics. MIDAS, Washington, May 2019.
39. Cauchemez S. Using mathematical models to understand and anticipate the spread of vector born diseases. Conférence mondiale organisée par la Croix Rouge "Santé et changements climatiques: Soigner une humanité à +2° », Cannes, April 2019.
40. Cauchemez S. Modèles mathématiques : faire comprendre les résultats. Colloque Maladies infectieuses Emergentes, Communication en situation d'émergence infectieuse, Ecole du Val-de-Grâce, Paris, March 2019.
41. Cauchemez S. Reconstruction de la dynamique des anticorps et de l'histoire des infections pour évaluer les risques liés à la dengue. XXIèmes Journées Francophones de Virologie, Lyon, March 2019.
42. Cauchemez S. Modèles mathématiques pour évaluer la propagation et le contrôle des agents infectieux dans les populations humaines. Colloque annuel de l'ITMO, Institut Pasteur, February 2019.
43. Cauchemez S. Modelling the spread of pathogens in human populations. The 26th Pasteur Weizmann meeting, integrative biology to battle emergin diseases, Institut Pasteur, Paris, November 2018.
44. Cauchemez S. Mathematical Models to assess the spread and control of pathogens. Eight Annual Meeting of Labex IBEID Integrative Biology of Emerging Infectious Diseases, Institut Pasteur, Paris, November 2018.
45. Cauchemez S. Planifier et répondre aux épidémies grâce aux modèles mathématiques. Journée des grands donateurs de l'Institut Pasteur, Institut Pasteur, January 2018.
46. Cauchemez S. Characterizing infectious disease transmission from detailed outbreak data. Plenary talk, Epidemics conference, Sitges, December 2017.
47. Cauchemez S. Predicting healthcare demand during epidemics in France. Next Generation Informatics for Global Health: Disease Dynamics and Digital Epidemiology, Hong Kong, July 2017.
48. Cauchemez S. Epidemic risk assessment: from understanding to control. AXA Country Risk Conference, Paris, May 2017.
49. Cauchemez S. Real-time epidemic analysis and modelling to inform policy making. Workshop "Preparedness, Prediction and Prevention of Emerging Zoonotic Viruses: Challenges and Opportunities", Gouvieux, April 2017.
50. Cauchemez S. Risque de microcéphalie lié à l'infection Zika durant la grossesse en Polynésie française. Journée Françaises de Virologie, Paris, March 2017.
51. Cauchemez S. Epidemic analysis and modelling: from understanding to control. Workshop Institut Pasteur 2025, Paris, February 2017.
52. Cauchemez S. Lessons from French Polynesia ZIKV and the risk of microcephaly during pregnancy. MIDAS, Washington, May 2016.
53. Cauchemez S. Real-time analysis and modelling of outbreaks to inform policy making. 115 Anniversary of ANSES animal health lab, Paris, May 2016.
54. Cauchemez S. Lessons from French Polynesia ZIKV and the risk of microcephaly during pregnancy. International Zika Summit 2016, Bringing together science and public health, Paris, April 2016.
55. Cauchemez S. The spread of pandemic influenza in two rural communities in 1920 and 2009: What has changed in a century? Incidence, Severity and Impact of Influenza, International Society for Influenza and Other Respiratory Virus Diseases (ISIRV), Paris, January 2016.
56. Cauchemez S. Quantifying the drivers of MERS-CoV transmission. British Ecology Society, Edimburg, December 2015.
57. Cauchemez S. Chikungunya: insights from mathematical models. Symposium Modeling chikungunya spread and control, American Society of Tropical Medicine and Hygiene, Philadelphia, November 2015.
58. Cauchemez S. Unravelling the drivers of MERS-CoV transmission. International meeting on respiratory pathogenes, Singapore, September 2015.
59. Cauchemez S. Modéliser l'épidémie d'Ebola : le cas de Conakry en Guinée. GDR Statistique et Santé, Paris, Juin 2015.
60. Cauchemez S. Epidemiological modelling of EVD in Conakry, Guinea. Targeting Ebola 2015, Recent advances and strategies, Institut Pasteur, May 2015.
61. Cauchemez S. Les modèles mathématiques à l'épreuve des infections virales. Journées française de virologie, Paris, April 2015.
62. Cauchemez S. Infectious diseases: characterizing transmission from incomplete epidemiological data. Conférence "Modeling, statistics and simulations in epidemiology", Lille, March 2015.
63. Cauchemez S. Mathematical modelling and the eradication of infectious diseases. Colloque sur le contrôle épidémiologique des maladies infectieuses, March 2015.
64. Cauchemez S. Epidemiological modeling of EVD chains of transmission and control in Conakry, Guinea. International conference on scientific insight and response of EVD, Beijing, March 2015.
65. Cauchemez S. Chains of transmission and control of EVD in Conakry, Guinea in 2014. WHO/LSHTM workshop on modelling Ebola in West Africa: data, epidemiology and interventions, London, March 2015.
66. Cauchemez S. Chains of transmission and control of EVD in Conakry, Guinea in 2014. Ebola 2015, challenging Ebola with a United Front, Oxford, January 2015.
67. Cauchemez S. Mathematical models of infectious diseases: Looking at the dynamics of spread to understand the mechanisms. Conférence du Conseil Scientifique de l'Institut Pasteur, January 2015.
68. Cauchemez S. Modelling of the Ebola epidemic. Colloque Ebola, Paris, December 2014.
69. Cauchemez S. MERS-COV and transmission scenarii. RICAI, Paris, November 2014.
70. Cauchemez S. Modelling the spread of chikungunya. Symposium: The Global Spread of Chikungunya: Epidemiology, Evolution, Pathogenesis and Global Needs, American Society of Tropical Medicine and Hygiene, New Orleans, November 2014.
71. Cauchemez S. Chains of transmission and control of Ebola Virus Disease in Conakry, Guinea in 2014. European Institute of Microbiology and Infectious Diseases, Berlin, October 2014.
72. Cauchemez S. Local and regional spread of chikungunya fever in the Americas. Symposium: Can one anticipate the next emerging infectious diseases in Europe? Labex IBEID, Institut Pasteur, September 2014.
73. Cauchemez S. Maximizing insights from limited surveillance data on zoonoses: Applications to MERS-CoV and influenza. Predemics-Antigone EU workshop, Institut Pasteur, Paris, November 2013.
74. Cauchemez S. Twenty years of statistical methods for the study of infectious disease dynamics. Infectious Disease Dynamics, Isaac Newton Institute for Mathematical Sciences, Cambridge, August 2013.

75. Cauchemez S. Selection bias and the interpretation of outbreak data: Application to the emergence of swine-origin H3N2v influenza in the US, MIDAS, Arlington, November 2012.
76. Cauchemez S. Influenza infection rates, measurement errors and the interpretation of paired serology. Statistical methods for infectious diseases, Open University, May 23rd-24th 2012.
77. Cauchemez S. Emergence of an influenza A(H3N2) variant virus in the United States: What is the epidemic potential? Director's briefing, CDC, Atlanta, February 2012.
78. Cauchemez S. The interpretation of paired serology. RAPIDD Immunodynamics workshop, Princeton, Oct 31st- Nov3rd 2011.
79. Cauchemez S. Role of social networks in shaping disease transmission during a community outbreak of 2009 H1N1 pandemic influenza. Infer (Inference For Epidemic-related Risk) Conference, Warwick University, March 2011.
80. Cauchemez S. Evaluating the impact of school closures on transmission during the 2009 H1N1 pandemic: from aggregated surveillance data to detailed outbreak investigations. Influenza A(H1N1) 2009 modelling and school closures working group meeting, ECDC, Stockholm, October 2010.
81. Cauchemez S. Summary of H1N1 school closure meeting (rapporteur). Surveillance and Studies in a Pandemic Meeting, ECDC, Stockholm, October 2010.
82. Cauchemez S. L'apport de la modélisation durant la pandémie de grippe H1N1. Ecole doctorale Pierre Louis, St Malo, France, October 2010.
83. Cauchemez S. Which measures of transmissibility and severity can we estimate in real-time? CDC meeting on Pandemic Impact Assessment, CDC, Atlanta, August 2010.
84. Cauchemez S., Bhattarai A et al. Contact networks and H1N1 pandemic influenza transmission inferred from a community outbreak. *MIDAS*, Washington, May 2010.
85. Cauchemez S. Role of modeling during the H1N1 pandemic (in French). Scientific workshop organized by Institut de Microbiologie et des Maladies Infectieuses and by INSERM. Annecy, France, June 2010.
86. Cauchemez S. Statistical analysis of outbreak data. WHO, Geneva, Switzerland, March 2010.
87. Cauchemez S., Ferguson NM. Dynamics of spread of H1N1. SAGE meeting, WHO, Geneva, Switzerland, November 2009.
88. Cauchemez S., Ferguson NM, Pellis L et al. Impact and use of school closure in the H1N1 pandemic. ECDC Influenza A(H1N1)v modelling working group, ECDC, Stockholm, Sweden, September 2009.
89. Cauchemez S. et al. Early investigations of the novel influenza A(H1N1) pandemic. Capstone Conference in "Challenges in Scientific Computing", Warwick, June 2009.
90. Cauchemez S. and Andrea Pugliese. Modelling the impact of intervention strategies. Meeting of the Health & Consumers Directorate-General section on influenza preparedness and response, European Commission, Luxembourg, April 2009.
91. Cauchemez S. Assumptions on influenza transmission gathered in Infrans. ECDC pandemic planning assumption meeting, ECDC, Stockholm, Sweden, January 2009.
92. Cauchemez S. What would be the potential health benefits of school closures in a pandemic? Eurogrippe conference organized by the French Presidency in liaison with the European Commission, Angers, France, Sept 3rd-5th 2008.
93. Cauchemez S. Real-time monitoring of infectious disease outbreaks. *Statistics for Public Health Surveillance*, The Open University, May 21st 2008.
94. Cauchemez S. Estimating the impact of school closure on influenza transmission from sentinel data. *NIDMA workshop modelling infectious diseases*, The National Centre for Immunization Research and Surveillance, Sydney, Australia, February 25th-27th 2008.
95. Cauchemez S. Dealing with missing data in longitudinal studies on transmission – Investigation of the heterogeneity in *S. pneumoniae* transmission. *NIDMA workshop modelling infectious diseases*, The National Centre for Immunization Research and Surveillance, Sydney, Australia, February 25th-27th 2008.
96. Cauchemez S. Fitting complex epidemiological models: From FMD to flu. *RAPIDD workshop on epidemic model hierarchies*, Forgarty Center, Washington DC, USA, January 22th 2008.
97. Cauchemez S. The role of mathematical models in pandemic preparedness. *17th European Congress of Clinical Microbiology and Infectious Diseases*, Munich, Germany, March 31st – April 3rd 2007.
98. Cauchemez S. Should we close schools during a flu pandemic?: Estimating school-based transmission from sentinel surveillance data. *Royal Statistical Society, General Applications Section, Epidemics and pandemics*, London, February 14th 2007.
99. Cauchemez S., Ferguson NM. A global dilemma: the pandemic threat of avian influenza. *Forum for influenza readiness and education*, Nice, France, November 17th-19th 2006.
100. Cauchemez S., Ferguson NM. How mathematical modelling can help in pandemic planning. *Statistical Ecology- Statistics and Animal population, International Biometric Society, British and Irish region*, Rothamsted, UK, November 15th 2006.
101. Cauchemez S., Temime L, Valleron AJ, Varon E, Thomas G, Guilletot D, Boelle PY. Investigating transmission parameters of communicable diseases from longitudinal data: The example of pneumococcal carriage in schools. *XXIII International Biometric Conference*, Montreal, Canada, July 16th-21th 2006.
102. Cauchemez S., Ferguson NM.. The role of mathematical modelling in pandemic preparedness. *First International Conference on Avian Influenza in Humans: Latest advances on prevention therapies and protective measures (Paris Anti-Avian Influenza 2006)*, Pasteur Institute, Paris, France, June 29th-30th 2006.
103. Cauchemez S. Transmission parameters and real-time estimation methods. *Influenza modelling workshop and exercise, Global Health Security Action Group (GHSAG)*, London, UK, June 1st-3rd 2005.

ORAL PRESENTATIONS

1. Cauchemez S. A new modelling framework to decipher the contributions of RNA viral loads dynamics on household transmission of SARS-CoV-2. Options for the control of influenza XII, Brisbane, September 2024.
2. Cauchemez S. Twenty years of research on school-based interventions during epidemics with applications to influenza. Conference of ANRS-MIE Coordinated Action on Modelling, November 2022.
3. Cauchemez S. Unravelling the key drivers of MERS-CoV transmission. *Epidemics*, Tampa, December 2015.
4. Cauchemez S. Quantifying the drivers of MERS-CoV transmission. *MIDAS*, Atlanta, April 2015.
5. Cauchemez S. What has happened to MERS-CoV?: Transmission scenarios for human novel coronavirus and how to tell them apart. *MIDAS*, Austin, May 2013.
6. Cauchemez S. How can we interpret limited and scarce surveillance data? Methodology session, Bill and Melinda Gates Foundation, Modelling Meeting, Seattle, June 2013. Organizer of the methodology session.

7. Cauchemez S. Monitoring the epidemic potential of zoonoses: application to the emergence of swine-origin A H3N2v virus in the United States. *Predemics*, Mallorca, October 2012.
8. Cauchemez S. Influenza, measurement errors and the interpretation of paired serology. *MIDAS*, Boston, Feb 1st-3rd 2012.
9. Cauchemez S. The interpretation of paired serology. *Epidemics* 3, Boston, Nov 30th – Dec 2nd 2011.
10. Cauchemez S., Bhattarai A et al. Social networks and H1N1 pandemic influenza transmission inferred from a community outbreak in Pennsylvania. *Options for the control of Influenza VII*, Hong Kong, Sept 3rd-7th 2010.
11. Cauchemez S., Donnelly CA et al. Household Transmission of 2009 Pandemic H1N1 influenza virus in the United States. *Epidemics* 2, Athens, Greece, Dec 10-12th 2009.
12. Cauchemez S., Valleron AJ et al. Estimating the impact of school closure on influenza transmission from sentinel data. *Epidemics*, Asilomar, USA, Dec 1st-3rd 2008.
13. Cauchemez S., Valleron AJ et al. Estimating the impact of school closure on influenza transmission from sentinel data. *ESWI*, Vilamora, Portugal, Sept 14th -17th 2008.
14. Cauchemez S., Carrat S et al. Analyse de la transmission de la grippe dans un suivi longitudinal de foyers. *ADELFI*, Bordeaux, France, 2004.
15. Cauchemez S., Temime L et al. A Bayesian approach to investigate *S. pneumoniae* carriage in a longitudinal follow-up of children in schools. *International Biometric Conference*, Cairns, Australia, 2004.
16. Cauchemez S., Temime L et al. A Bayesian approach to investigate *S. pneumoniae* carriage in a follow-up of children in schools. *ISPPD-4*, Helsinki, Finland, 2004.

SEMINARS

1. Cauchemez S. Studying the transmission of infectious diseases in a context of missing data. MAP seminar, Paris, January 2026.
2. Cauchemez S. Analysing household studies to decipher the drivers of infectious disease transmission, susceptibility and infectivity. Oxford University, March 2025.
3. Cauchemez S. Analysing household studies to decipher the drivers of infectious disease transmission, susceptibility and infectivity. Institut Pasteur du Cambodge, April 2025.
4. Cauchemez S. Analysing household studies to decipher the drivers of infectious disease transmission, susceptibility and infectivity. Imperial College London, London, March 2025.
5. Cauchemez S. Using mathematical models to analyze complex epidemic data and gain key insights on epidemic dynamics and control. National Institute of Infectious Diseases, Japan, April 2023.
6. Cauchemez S. Modelling the impact of COVID-19 vaccines. Haute Autorité de Santé, January 2023.
7. Cauchemez S. More than 2 years of COVID-19 modelling to understand disease spread and control and support policy making in France. Bocconi COVID crisis lab, Italy, September 2022.
8. Cauchemez S. Modélisation des pandémies. Journées de prospective LKB, June 2022.
9. Cauchemez S. Predictive epidemiology: From Influenza to COVID. Société Française de Microbiology, September 2021.
10. Cauchemez S. Estimating the number of persons infected by SARS-CoV-2. Modcov, January 2021.
11. Cauchemez S. Peut-on anticiper le devenir d'une épidémie. Collège de France, December 2019.
12. Cauchemez S. Epidemic modelling: At the interface between science and policy making. Matinales du Centre de Recherche Translationnel, Institut Pasteur, Paris, July 2017.
13. Cauchemez S. Analysis and modelling of infectious disease epidemics: from understanding to control. Korean CDC, Seoul, July 2017.
14. Cauchemez S. Analysis and modelling of epidemics. Institut Pasteur de Dakar, Senegal, June 2017.
15. Cauchemez S. Real-time assessment of health-care requirements during the Zika epidemic in Martinique. Santé Publique France, May 2017.
16. Cauchemez S. Characterizing the spread of arboviruses. London School of Hygiene and Tropical Medicine, London, April 2017.
17. Cauchemez S. Epidemic modelling: at the interface between science and policy making. INRA, Jouy-en-Josas, March 2017.
18. Cauchemez S. Epidemic modelling: at the interface between science and policy making. UMR 738, University Paris Diderot, Paris, March 2017.
19. Cauchemez S. Chains of transmission and control of EVD in Conakry, Guinea in 2014. Institut de Veille Sanitaire, Paris, April 2015.
20. Cauchemez S. Chains of transmission and control of EVD in Conakry, Guinea in 2014. Harvard School of Public Health, Boston, February 2015.
21. Cauchemez S. Mathematical models for the epidemic and for the infection. Institut Pasteur de Madagascar, Mar 2014.
22. Cauchemez S. Mathematical models for the epidemic and for the infection. Institut Pasteur de Guyane, Feb 2014.
23. Cauchemez S. Mathematical models for the epidemic and for the infection. Away day of the Department of Epidemiology and Infection, Institut Pasteur, Sept 2013.
24. Cauchemez S. The contribution of modelling to the analysis of epidemic data. Pasteur Institute, Paris, April 2012.
25. Cauchemez S. Statistical models for infectious disease data. Pasteur Institute, Paris, Dec 7th 2011.
26. Cauchemez S. Estimating the transmission characteristics of an infectious disease: the case of influenza. University of Nottingham, Nottingham, June 20th 2011.
27. Cauchemez S. Inferring transmission characteristics of influenza: from aggregated surveillance data to detailed outbreak investigations. Université Paris Descartes, Paris, April 8th 2011.
28. Cauchemez S. Inferring transmission characteristics of influenza: from aggregated surveillance data to detailed outbreak investigations. Heriot-Watt University, Edinburgh, March 9th 2011.
29. Cauchemez S. Inferring transmission characteristics of influenza: from aggregated surveillance data to detailed outbreak investigations. Department of Epidemiology and Public Health, Imperial College, May 2010.
30. Cauchemez S. Estimating the impact of school closure on influenza transmission from Sentinel data. MRC Biostatistics Unit, Institute of Public Health, Cambridge, January 2009.
31. Cauchemez S. Assessing the impact of non-pharmaceutical interventions during a pandemic. *MIDAS meeting*, Monterey, USA, Dec 4th 2008.
32. Cauchemez S. Statistics for the real-time monitoring of a pandemic. *ECDC nowcasting and short term forecasting*, Stockholm, Nov 29th 2007.
33. Cauchemez S. Estimation of highly structured epidemic models based on Importance Sampling. *Statistics seminar, University of Bristol*, London, April 20th 2007.
34. Cauchemez S. Should we close schools during a flu pandemic?: Estimating school-based transmission from sentinel surveillance data. *Health Protection Agency, Modelling Seminar*, London, March 23rd 2007.
35. Cauchemez S. Rôle des modèles mathématiques dans la préparation à une pandémie. *Secrétariat Général de la Défense Nationale*, Paris, France, December 11th 2006.

36. Cauchemez S. Investigating heterogeneity in pneumococcal transmission: A Bayesian MCMC approach applied to a follow-up of schools. *Statistics seminar*, University of Nottingham, UK, December 7th 2006.
37. Cauchemez S. Etude de la transmission de *S. pneumoniae*: une approche bayésienne appliquée au suivi longitudinal d'enfants dans des maternelles, *Séminaire de l'unité INSERM 657*, Paris, France, June 19th 2006.
38. Cauchemez S. Investigating heterogeneity in pneumococcal transmission: A Bayesian MCMC approach applied to a follow-up of schools, *Modelling & Economics Unit Seminar Series*, Heath Protection Agency, London, UK, June 8th 2006.

POSTER PRESENTATIONS

1. Yu H*, Cauchemez S*[†] et al. Pandemic Influenza A(H1N1) in China, May-November 2009. *Options for the control of Influenza VII*, Hong Kong, September 3rd-7th 2010. * equal contribution ; [†] presenting author.
2. Cauchemez S, Temime L et al. Analyse du portage de *S. pneumoniae* dans les écoles. *ADELFI*, Bordeaux, France, 2004.
3. Cauchemez S, Carrat F et al. Estimating influenza transmission in a longitudinal follow-up of households. *International Biometric Conference*, Cairns, Australia, 2004.
4. Cauchemez S, Carrat F et al. Estimating influenza transmission in households by MCMC sampling. *International Conference on Options for the Control of Influenza*, Okinawa, Japan, 2003.